# EDGAR Filing Document

**Accession Number:** 0000058411
**File Stem:** 0001393905-23-000034
**Filing Date:** 2023-1
**Character Count:** 205027
**Document Hash:** 93986233384f3db26924a5958d7fe81a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001393905-23-000034.hdr.sgml**: 20230119

**ACCESSION NUMBER**: 0001393905-23-000034

**CONFORMED SUBMISSION TYPE**: 253G1

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230119

**DATE AS OF CHANGE**: 20230119

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lee Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0000058411
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374]
- **IRS NUMBER:** 952680312
- **STATE OF INCORPORATION:** CO
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 253G1
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 024-11991
- **FILM NUMBER:** 23538103

**BUSINESS ADDRESS:**
- **STREET 1:** 30 N GOULD STREET
- **STREET 2:** SUITE 5835
- **CITY:** SHERIDAN
- **STATE:** WY
- **ZIP:** 82801
- **BUSINESS PHONE:** 307-278-1360

**MAIL ADDRESS:**
- **STREET 1:** 30 N GOULD STREET
- **STREET 2:** SUITE 5835
- **CITY:** SHERIDAN
- **STATE:** WY
- **ZIP:** 82801

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LEE PHARMACEUTICALS
- **DATE OF NAME CHANGE:** 19920703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LEE INDUSTRIES INC
- **DATE OF NAME CHANGE:** 19720113

**Filed Pursuant to Rule 253(g)(1)**

**Offering File Number: 024-11991**

**OFFERING CIRCULAR SUPPLEMENT NO. 1**

**Date of Qualification of the Offering Circular: January 17, 2023**

**LEE PHARMACEUTICALS, INC.**

**11 N Water Street**

**Mobile, AL 36602**

**(307) 278-1360**

**January 19, 2023**

This document (the "Supplement") supplements the Offering Statement filed on Form 1-A of Lee Pharmaceuticals, Inc. (the "Company"), filed on September 13, 2022 (the "Offering Circular") relating to the offer and sale by us of 5,000,000,000,000 shares of our common stock (the "Shares"). Any inconsistent information made by us in a previous offering circular supplement or post-qualification amendment is modified or superseded by the information contained in this Supplement. Unless otherwise defined in this Supplement, capitalized terms used herein shall have the same meanings as set forth in the Offering Circular, including the disclosures incorporated by reference therein.

***Final Pricing***

The purpose of this supplement is to amend the final pricing of the offering. The Shares will be offered at a price of $0.01 per share, for a total aggregate offering amount of $50,000,000.

***SEC Disclaimer***

An offering statement regarding the offering described in the Offering Circular has been filed with the Commission. The Commission has qualified that offering statement, which only means that the Company may make sales of the securities described by that offering statement. It does not mean that the Commission has approved, passed upon the merits, or passed upon the accuracy or completeness of the information in the offering statement. You should read the Offering Circular before making any investment.

This Supplement to the Offering Circular does not otherwise modify or update disclosure in, or exhibits to, the original Offering Circular. This Supplement to the Offering Circular should be read in conjunction with the Offering Circular and is qualified by reference to the Offering Circular except to the extent that the information contained herein supplements the information contained in the Offering Circular.

------

i

------

SEC File No. 024-11991

**U.S. SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 1-A/A**

**Dated: January 19, 2023**

**REGULATION A OFFERING CIRCULAR UNDER THE SECURITIES ACT OF 1933**

**Lee Pharmaceuticals, Inc.**

(Exact name of issuer as specified in its charter)

**Colorado**

(State of other jurisdiction of incorporation or organization)

**11 N Water Street**

**Mobile, AL 36602**

**(307) 278-1360**

(Address, including zip code, and telephone number,

including area code of issuer's principal executive office)

**Jeff Turner**

**897 W Baxter Dr.**

**South Jordan, UT 84095**

**801-810-4465**

(Name, address, including zip code, and telephone number,

including area code, of agent for service)

---

| | |
|:---|:---|
| **2821** | **95-2680312** |
| (Primary Standard Industrial<br> Classification Code Number) | (I.R.S. Employer<br> Identification Number) |

---

This Preliminary Offering Circular shall only be qualified upon order of the Commission, unless a subsequent amendment is filed indicating the intention to become qualified by operation of the terms of Regulation A.

This Offering Circular is following the Offering Circular format described in Part II (a)(1)(ii) of Form 1-A.

.

------

ii

------

**PART II - PRELIMINARY OFFERING CIRCULAR - FORM 1-A: TIER II**

**An Offering statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission. Information contained in this Preliminary Offering Circular is subject to completion or amendment. These securities may not be sold nor may offers to buy be accepted before the Offering statement filed with the Securities and Exchange Commission is qualified. This Preliminary Offering Circular shall not constitute an offer to sell or the solicitation of an offer to buy nor may there be any sales of these securities in any state in which such offer, solicitation or sale would be unlawful before registration or qualification under the laws of any such state. We may elect to satisfy our obligation to deliver a Final Offering circular by sending you a notice within two business days after the completion of our sale to you that contains the URL where the Final Offering Circular or the Offering statement in which such Final Offering Circular was filed may be obtained.**

**PRELIMINARY OFFERING CIRCULAR**

**Dated: January 19, 2023**

**PURSUANT TO REGULATION A OF THE SECURITIES ACT OF 1933**

**Lee Pharmaceuticals, Inc.**

**11 N Water Street**

**Mobile, AL 36602**

5,000,000,000 shares of Common Stock at a price of $0.01 per share

Minimum Investment: $1,000

Maximum Offering: $50,000,000

See The Offering - Page 9 and Securities Being Offered - Page 31 For Further Details. None of the Securities Offered Are Being Sold By Present Security Holders. This Offering Will Commence Upon Qualification of this Offering by the Securities and Exchange Commission and Will Terminate 365 days from the date of qualification by the Securities And Exchange Commission, Unless Extended or Terminated Earlier By The Issuer.

**PLEASE REVIEW ALL RISK FACTORS ON PAGES 10 THROUGH PAGE 18 BEFORE MAKING AN INVESTMENT IN THIS COMPANY. AN INVESTMENT IN THIS COMPANY SHOULD ONLY BE MADE IF YOU ARE CAPABLE OF EVALUATING THE RISKS AND MERITS OF THIS INVESTMENT AND IF YOU HAVE SUFFICIENT RESOURCES TO BEAR THE ENTIRE LOSS OF YOUR INVESTMENT, SHOULD THAT OCCUR.**

**THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION DOES NOT PASS UPON THE MERITS OF OR GIVE ITS APPROVAL TO ANY SECURITIES OFFERED OR THE TERMS OF THE OFFERING, NOR DOES IT PASS UPON THE ACCURACY OR COMPLETENESS OF ANY OFFERING CIRCULAR OR OTHER SELLING LITERATURE. THESE SECURITIES ARE OFFERED PURSUANT TO AN EXEMPTION FROM REGISTRATION WITH THE COMMISSION; HOWEVER, THE COMMISSION HAS NOT MADE AN INDEPENDENT DETERMINATION THAT THE SECURITIES OFFERED HEREUNDER ARE EXEMPT FROM REGISTRATION.**

------

iii

------

Because these securities are being offered on a "best efforts" basis, the following disclosures are hereby made:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Price to Public** | &nbsp;&nbsp;**Commissions <sup>(1)</sup>** | &nbsp;&nbsp;**Proceeds to**<br> **Company <sup>(2)</sup>** | &nbsp;&nbsp;**Proceeds to**<br> **Other Persons <sup>(3)</sup>** |
| &nbsp;&nbsp;Per Share | &nbsp;&nbsp;$0.01 | &nbsp;&nbsp;$0 | &nbsp;&nbsp;$0.01 |  |
| &nbsp;&nbsp;Minimum Investment | &nbsp;&nbsp;$1000 | &nbsp;&nbsp;$0 | &nbsp;&nbsp;$1000 |  |
| &nbsp;&nbsp;Maximum Offering | &nbsp;&nbsp;$50000000 | &nbsp;&nbsp;$0 | &nbsp;&nbsp;$50000000 |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Company has not presently engaged an underwriter for the sale of securities under this Offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Does not reflect payment of expenses of this Offering, which are estimated to not exceed $25,000.00 and which include, among other things, legal fees, accounting costs, reproduction expenses, due diligence, marketing, consulting, administrative services other costs of blue-sky compliance, and actual out-of-pocket expenses incurred by the Company selling the Shares. This amount represents the proceeds of the offering to the Company, which will be used as set out in "USE OF PROCEEDS TO ISSUER."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)There are no finder's fees or other fees being paid to third parties from the proceeds. See 'PLAN OF DISTRIBUTION.'

This Offering (the "Offering") consists of 5,000,000,000 shares of Common Stock (the "Shares" or individually, each a "Share") that is being offered on a "best efforts" basis, which means that there is no guarantee that any minimum amount will be sold. The Shares are being offered and sold by Lee Pharmaceuticals, Inc., a Colorado Corporation (the "Company"). We are offering up to 5,000,000,000 shares at a price of $0.01 per share. This Offering has a minimum purchase of $1,000 per investor. We may waive the minimum purchase requirement on a case-by-case basis in our sole discretion. The Shares are being offered only by the Company on a best-efforts basis to an unlimited number of accredited investors and to an unlimited number of non-accredited investors subject to the limitations of Regulation A. Under Rule 251(d)(2)(i)(C) of Regulation A+, non-accredited, non-natural investors are subject to the investment limitation and may only invest funds which do not exceed 10% of the greater of the purchaser's revenue or net assets (as of the purchaser's most recent fiscal year end). A non-accredited, natural person may only invest funds which do not exceed 10% of the greater of the purchaser's annual income or net worth (please see below on how to calculate your net worth). The maximum aggregate amount of the Shares that will be offered is 5,000,000,000 shares of Common Stock with a Maximum Offering Price of $50,000,000. There is no minimum number of Shares that needs to be sold in order for funds to be released to the Company and for this Offering to close.

Our Common Stock is currently quoted on the OTC Pink tier of the OTC Market Group, Inc. under the symbol "LPHM". On September 8, 2022, the last reported sale price of our common stock was $0.1638.

The Shares are being offered pursuant to Regulation A of Section 3(b) of the Securities Act of 1933, as amended, for Tier 2 offerings. The Shares will only be issued to purchasers who satisfy the requirements set forth in Regulation A. The offering is expected to expire on the first of: (i) all of the Shares offered are sold; or (ii) the close of business 365 days from the date of qualification by the Commission, unless sooner terminated or extended by the Company's CEO. Pending each closing, payments for the Shares will be paid directly to the Company. Funds will be immediately transferred to the Company where they will be available for use in the operations of the Company's business in a manner consistent with the "USE OF PROCEEDS TO ISSUER" in this Offering Circular.

**THIS OFFERING CIRCULAR DOES NOT CONSTITUTE AN OFFER OR SOLICITATION IN ANY JURISDICTION IN WHICH SUCH AN OFFER OR SOLICITATION WOULD BE UNLAWFUL. NO PERSON HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATIONS CONCERNING THE COMPANY OTHER THAN THOSE CONTAINED IN THIS OFFERING CIRCULAR, AND IF GIVEN OR MADE, SUCH OTHER INFORMATION OR REPRESENTATION MUST NOT BE RELIED UPON.**

**PROSPECTIVE INVESTORS ARE NOT TO CONSTRUE THE CONTENTS OF THIS OFFERING CIRCULAR, OR OF ANY PRIOR OR SUBSEQUENT COMMUNICATIONS FROM THE COMPANY OR ANY OF ITS EMPLOYEES, AGENTS OR AFFILIATES, AS INVESTMENT, LEGAL, FINANCIAL OR TAX ADVICE.**

------

iv

------

GENERALLY, NO SALE MAY BE MADE TO YOU IN THIS OFFERING IF THE AGGREGATE PURCHASE PRICE YOU PAY IS MORE THAN 10% OF THE GREATER OF YOUR ANNUAL INCOME OR NET WORTH. DIFFERENT RULES APPLY TO ACCREDITED INVESTORS AND NON-NATURAL PERSONS. BEFORE MAKING ANY REPRESENTATION THAT YOUR INVESTMENT DOES NOT EXCEED APPLICABLE THRESHOLDS, WE ENCOURAGE YOU TO REVIEW RULE 251(d)(2)(i)(C) OF REGULATION A. FOR GENERAL INFORMATION ON INVESTING, WE ENCOURAGE YOU TO REFER TO WWW.INVESTOR.GOV (WHICH IS NOT INCORPORATED BY REFERENCE INTO THIS OFFERING CIRCULAR).

This Offering is inherently risky. See "Risk Factors" beginning on page 10.

Sales of these securities will commence within two calendar days of the qualification date and the filing of a Form 253(g)(2) Offering Circular AND it will be a continuous Offering pursuant to Rule 251(d)(3)(i)(F).

The Company is following the "Offering Circular" format of disclosure under Regulation A.

**AN OFFERING STATEMENT PURSUANT TO REGULATION A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. INFORMATION CONTAINED IN THIS PRELIMINARY OFFERING CIRCULAR IS SUBJECT TO COMPLETION OR AMENDMENT. THESE SECURITIES MAY NOT BE SOLD NOR MAY OFFERS TO BUY BE ACCEPTED BEFORE THE OFFERING STATEMENT FILED WITH THE COMMISSION IS QUALIFIED. THIS PRELIMINARY OFFERING CIRCULAR SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR MAY THERE BE ANY SALES OF THESE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL BEFORE REGISTRATION OR QUALIFICATION UNDER THE LAWS OF SUCH STATE. THE COMPANY MAY ELECT TO SATISFY ITS OBLIGATION TO DELIVER A FINAL OFFERING CIRCULAR BY SENDING YOU A NOTICE WITHIN TWO BUSINESS DAYS AFTER THE COMPLETION OF THE COMPANY'S SALE TO YOU THAT CONTAINS THE URL WHERE THE FINAL OFFERING CIRCULAR OR THE OFFERING STATEMENT IN WHICH SUCH FINAL OFFERING CIRCULAR WAS FILED MAY BE OBTAINED.**

**NASAA UNIFORM LEGEND**

**FOR RESIDENTS OF ALL STATES: THE PRESENCE OF A LEGEND FOR ANY GIVEN STATE REFLECTS ONLY THAT A LEGEND MAY BE REQUIRED BY THAT STATE AND SHOULD NOT BE CONSTRUED TO MEAN AN OFFER OR SALE MAY BE MADE IN A PARTICULAR STATE. IF YOU ARE UNCERTAIN AS TO WHETHER OR NOT OFFERS OR SALES MAY BE LAWFULLY MADE IN ANY GIVEN STATE, YOU ARE HEREBY ADVISED TO CONTACT THE COMPANY. THE SECURITIES DESCRIBED IN THIS OFFERING CIRCULAR HAVE NOT BEEN REGISTERED UNDER ANY STATE SECURITIES LAWS (COMMONLY CALLED 'BLUE SKY' LAWS).**

**IN MAKING AN INVESTMENT DECISION INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE PERSON OR ENTITY CREATING THE SECURITIES AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. THESE SECURITIES HAVE NOT BEEN RECOMMENDED BY ANY FEDERAL OR STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY. FURTHERMORE, THE FOREGOING AUTHORITIES HAVE NOT CONFIRMED THE ACCURACY OR DETERMINED THE ADEQUACY OF THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.**

**NOTICE TO FOREIGN INVESTORS**

**IF THE PURCHASER LIVES OUTSIDE THE UNITED STATES, IT IS THE PURCHASER'S RESPONSIBILITY TO FULLY OBSERVE THE LAWS OF ANY RELEVANT TERRITORY OR JURISDICTION OUTSIDE THE UNITED STATES IN CONNECTION WITH ANY PURCHASE OF THE SECURITIES, INCLUDING OBTAINING REQUIRED GOVERNMENTAL OR OTHER CONSENTS OR OBSERVING ANY OTHER REQUIRED LEGAL OR OTHER FORMALITIES. THE COMPANY** 

------

v

------

**RESERVES THE RIGHT TO DENY THE PURCHASE OF THE SECURITIES BY ANY FOREIGN PURCHASER.**

**PATRIOT ACT RIDER**

The Investor hereby represents and warrants that Investor is not, nor is it acting as an agent, representative, intermediary or nominee for, a person identified on the list of blocked persons maintained by the Office of Foreign Assets Control, U.S. Department of Treasury. In addition, the Investor has complied with all applicable U.S. laws, regulations, directives, and executive orders relating to anti-money laundering , including but not limited to the following laws: (1) the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001, Public Law 107-56, and (2) Executive Order 13224 (Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism) of September 23, 2001.

**NO DISQUALIFICATION EVENT ("BAD ACTOR" DECLARATION)**

**NONE OF THE COMPANY, ANY OF ITS PREDECESSORS, ANY AFFILIATED ISSUER, ANY DIRECTOR, EXECUTIVE OFFICER, OTHER OFFICER OF THE COMPANY PARTICIPATING IN THE OFFERING CONTEMPLATED HEREBY, ANY BENEFICIAL OWNER OF 20% OR MORE OF THE COMPANY'S OUTSTANDING VOTING EQUITY SECURITIES, CALCULATED ON THE BASIS OF VOTING POWER, NOR ANY PROMOTER (AS THAT TERM IS DEFINED IN RULE 405 UNDER THE SECURITIES ACT OF 1933) CONNECTED WITH THE COMPANY IN ANY CAPACITY AT THE TIME OF SALE (EACH, AN "***ISSUER COVERED PERSON***") IS SUBJECT TO ANY OF THE "BAD ACTOR" DISQUALIFICATIONS DESCRIBED IN RULE 506(D)(1)(I) TO (VIII) UNDER THE SECURITIES ACT OF 1933 (A "***DISQUALIFICATION EVENT***"), EXCEPT FOR A DISQUALIFICATION EVENT COVERED BY RULE 506(D)(2) OR (D)(3) UNDER THE SECURITIES ACT. THE COMPANY HAS EXERCISED REASONABLE CARE TO DETERMINE WHETHER ANY ISSUER COVERED PERSON IS SUBJECT TO A DISQUALIFICATION EVENT.**

**Continuous Offering**

Under Rule 251(d)(3) to Regulation A, the following types of continuous or delayed Offerings are permitted, among others: (1) securities offered or sold by or on behalf of a person other than the issuer or its subsidiary or a person of which the issuer is a subsidiary; (2) securities issued upon conversion of other outstanding securities; or (3) securities that are part of an Offering which commences within two calendar days after the qualification date. These may be offered on a continuous basis and may continue to be offered for a period in excess of 30 days from the date of initial qualification. They may be offered in an amount that, at the time the Offering statement is qualified, is reasonably expected to be offered and sold within one year from the initial qualification date. No securities will be offered or sold "at the market." The Shares will be sold at a fixed price to be determined after qualification. We have provided a bona fide estimate of the price range of the Offering, pursuant to Rule 253(b)(2). The Offering Price will be filed by the Company via an offering circular supplement pursuant to Rule 253(c). The supplement will not, in the aggregate, represent any change from the maximum aggregate Offering Price calculable using the information in the qualified Offering statement. This information will be filed no later than two business days following the earlier of the date of determination of such pricing information or the date of first use of the Offering Circular after qualification.

Sale of these shares will commence within two calendar days of the qualification date, and it will be a continuous Offering pursuant to Rule 251(d)(3)(i)(F).

Subscriptions are irrevocable and the purchase price is non-refundable as expressly stated in this Offering Circular. The Company, by determination of the Board of Directors, in its sole discretion, may issue the Securities under this Offering for cash, promissory notes, services, and/or other consideration without notice to subscribers. All proceeds received by the Company from subscribers for this Offering will be available for use by the Company upon acceptance of subscriptions for the Securities by the Company.

------

vi

------

**Forward Looking Statement Disclosure**

**This Form 1-A, Offering Circular, and any documents incorporated by reference herein or therein contain forward-looking statements and are subject to risks and uncertainties. All statements other than statements of historical fact or relating to present facts or current conditions included in this Form 1-A, Offering Circular, and any documents incorporated by reference are forward-looking statements. Forward-looking statements give the Company's current reasonable expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance, and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as 'anticipate,' 'estimate,' 'expect,' 'project,' 'plan,' 'intend,' 'believe,' 'may,' 'should,' 'can have,' 'likely' and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. The forward-looking statements contained in this Form 1-A, Offering Circular, and any documents incorporated by reference herein or therein are based on reasonable assumptions the Company has made in light of its industry experience, perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. As you read and consider this Form 1-A, Offering Circular, and any documents incorporated by reference, you should understand that these statements are not guarantees of performance or results. They involve risks, uncertainties (many of which are beyond the Company's control) and assumptions. Although the Company believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect its actual operating and financial performance and cause its performance to differ materially from the performance anticipated in the forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of these assumptions prove incorrect or change, the Company's actual operating and financial performance may vary in material respects from the performance projected in these forward- looking statements. Any forward-looking statement made by the Company in this Form 1-A, Offering Circular or any documents incorporated by reference herein speaks only as of the date of this Form 1-A, Offering Circular or any documents incorporated by reference herein. Factors or events that could cause our actual operating and financial performance to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.**

**About This Form 1-A/A and Offering Circular**

**In making an investment decision, you should rely only on the information contained in this Form 1-A/A and Offering Circular. The Company has not authorized anyone to provide you with information different from that contained in this Form 1-A/A and Offering Circular. We are offering to sell, and seeking offers to buy the Shares only in jurisdictions where offers and sales are permitted. You should assume that the information contained in this Form 1-A/A and Offering Circular is accurate only as of the date of this Form 1-A/A and Offering Circular, regardless of the time of delivery of this Form 1-A/A and Offering Circular. Our business, financial condition, results of operations, and prospects may have changed since that date. Statements contained herein as to the content of any agreements or other documents are summaries and, therefore, are necessarily selective and incomplete and are qualified in their entirety by the actual agreements or other documents.**

------

vii

------

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| &nbsp;&nbsp;[OFFERING CIRCULAR SUMMARY, PERKS AND RISK FACTORS](#_OFFERING_CIRCULAR_SUMMARY,) | &nbsp;&nbsp;9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Offering Circular Summary](#_Offering_Circular_Summary) | &nbsp;&nbsp;9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[The Offering](#_The_Offering) | &nbsp;&nbsp;10 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Investment Analysis](#_Investment_Analysis) | &nbsp;&nbsp;10 |
| &nbsp;&nbsp;[RISK FACTORS](#_RISK_FACTORS) | &nbsp;&nbsp;11 |
| &nbsp;&nbsp;[DETERMINATION OF OFFERING PRICE](#_DETERMINATION_OF_OFFERING) | &nbsp;&nbsp;20 |
| &nbsp;&nbsp;[DILUTION](#_DILUTION) | &nbsp;&nbsp;20 |
| &nbsp;&nbsp;[PLAN OF DISTRIBUTION](#_PLAN_OF_DISTRIBUTION) | &nbsp;&nbsp;21 |
| &nbsp;&nbsp;[USE OF PROCEEDS TO ISSUER](#_USE_OF_PROCEEDS_1) | &nbsp;&nbsp;22 |
| &nbsp;&nbsp;[USE OF PROCEEDS](#_USE_OF_PROCEEDS) | &nbsp;&nbsp;23 |
| &nbsp;&nbsp;[DESCRIPTION OF BUSINESS](#_DESCRIPTION_OF_BUSINESS) | &nbsp;&nbsp;23 |
| &nbsp;&nbsp;[MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS](#_MANAGEMENT___S_DISCUSSION_AND) | &nbsp;&nbsp;25 |
| &nbsp;&nbsp;[DIRECTORS, EXECUTIVE OFFICERS AND SIGNIFICANT EMPLOYEES](#_DIRECTORS,_EXECUTIVE_OFFICERS) | &nbsp;&nbsp;27 |
| &nbsp;&nbsp;[INTEREST OF MANAGEMENT AND OTHERS IN CERTAIN TRANSACTIONS](#_INTEREST_OF_MANAGEMENT) | &nbsp;&nbsp;29 |
| &nbsp;&nbsp;[DESCRIPTION OF SECURITIES](#_DESCRIPTION_OF_SECURITIES) | &nbsp;&nbsp;29 |
| &nbsp;&nbsp;[SECURITIES BEING OFFERED](#_SECURITIES_BEING_OFFERED) | &nbsp;&nbsp;30 |
| &nbsp;&nbsp;[DISQUALIFYING EVENTS DISCLOSURE](#_DISQUALIFYING_EVENTS_DISCLOSURE) | &nbsp;&nbsp;31 |
| &nbsp;&nbsp;[ERISA CONSIDERATIONS](#_ERISA_CONSIDERATIONS) | &nbsp;&nbsp;31 |
| &nbsp;&nbsp;[DIVIDEND POLICY](#_DIVIDEND_POLICY) | &nbsp;&nbsp;32 |
| &nbsp;&nbsp;[SHARES ELIGIBLE FOR FUTURE SALE](#_SHARES_ELIGIBLE_FOR) | &nbsp;&nbsp;33 |
| &nbsp;&nbsp;[INVESTOR ELIGIBILITY STANDARDS & ADDITIONAL INFORMATION ABOUT THE OFFERING](#_INVESTOR_ELIGIBILITY_STANDARDS) | &nbsp;&nbsp;33 |
| &nbsp;&nbsp;[LEGAL MATTERS](#_LEGAL_MATTERS) | &nbsp;&nbsp;35 |
| &nbsp;&nbsp;[REPORTS](#_REPORTS) | &nbsp;&nbsp;35 |
| &nbsp;&nbsp;[WHERE YOU CAN FIND MORE INFORMATION](#_WHERE_YOU_CAN) | &nbsp;&nbsp;35 |
| &nbsp;&nbsp;[SIGNATURES](#_SIGNATURES) | &nbsp;&nbsp;36 |
| &nbsp;&nbsp;[PART III: EXHIBITS](#_PART_III:_EXHIBITS) | &nbsp;&nbsp;37 |
| &nbsp;&nbsp;[PART F/S: FINANCIAL STATEMENTS](#_PART_F/S:_FINANCIAL) | &nbsp;&nbsp;38 |

---

------

viii

------

**OFFERING CIRCULAR SUMMARY, PERKS AND RISK FACTORS**

**Offering Circular Summary**

*The following summary is qualified in its entirety by the more detailed information appearing elsewhere in this Offering Circular and/or incorporated by reference in this Offering Circular. For full offering details, please (1) thoroughly review this Form 1-A/A filed with the Securities and Exchange Commission (2) thoroughly review this Offering Circular and (3) thoroughly review any attached documents to or documents referenced in, this Form 1-A/A and Offering Circular.*

*Unless otherwise indicated, the terms "Lee Pharmaceuticals," "LPHM," "the Company," we," "our," and "us" are used in this Offering Circular to refer to Lee Pharmaceuticals, Inc. and its subsidiaries.*

**Business Overview**

Lee Pharmaceuticals, Inc., a Colorado corporation, is a technology company that is currently developing a lifestyle and wellness application to be offered through the Google Play Store and Apple App Store. For further information about the Company and its plan of operations, see the section entitled "Description of Business" beginning on page 23.

---

| | |
|:---|:---|
| &nbsp;&nbsp;Issuer: | &nbsp;&nbsp;Lee Pharmaceuticals, Inc. |
| &nbsp;&nbsp;Type of Stock Offering: | &nbsp;&nbsp;Common Stock |
| &nbsp;&nbsp;Price Per Share: | &nbsp;&nbsp;$0.01 |
| &nbsp;&nbsp;Minimum Investment: | &nbsp;&nbsp;$1,000 per investor. We may waive the minimum purchase requirement on a case-by-case basis in our sole discretion. |
| &nbsp;&nbsp;Maximum Offering: | &nbsp;&nbsp;$50,000,000. The Company will not accept investments that would be, in aggregate, greater than the Maximum Offering amount. |
| &nbsp;&nbsp;Maximum Shares Offered: | &nbsp;&nbsp;5,000,000,000 shares of Common Stock |
| &nbsp;&nbsp;Investment Amount Restrictions: | &nbsp;&nbsp;Generally, no sale may be made to you in this offering if the aggregate purchase price you pay is more than 10% of the greater of your annual income or net worth. Different rules apply to accredited investors and non-natural persons. Before making any representation that your investment does not exceed applicable thresholds, we encourage you to review Rule 251(d)(2)(i)(c) of Regulation A. For general information on investing, we encourage you to refer to www.investor.gov. |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;Method of Subscription: | &nbsp;&nbsp;After the qualification by the SEC of the Offering Statement of which this Offering Circular is a part, investors can subscribe to purchase the Shares by completing the Subscription Agreement and sending payment by check, wire transfer, ACH, credit card, or any other payment method accepted by the Company. Upon the approval of any subscription, the Company shall immediately deposit said proceeds into the bank account of the Company and may dispose of the proceeds in accordance with the Use of Proceeds. Subscriptions are irrevocable and the purchase price is non-refundable. |
| &nbsp;&nbsp;Use of Proceeds: | &nbsp;&nbsp;See the description in the section entitled "USE OF PROCEEDS TO ISSUER" on page 21 herein. |
| &nbsp;&nbsp;Voting Rights: | &nbsp;&nbsp;The Shares have full voting rights. |
| &nbsp;&nbsp;Trading Symbols: | &nbsp;&nbsp;Our common stock is directly quoted on the OTC Pink tier of the OTC Market Group, Inc. under the symbol "LPHM". |
| &nbsp;&nbsp;Transfer Agent and Registrar: | &nbsp;&nbsp;Issuer Direct Corporation is our transfer agent and registrar in connection with the Offering. |
| &nbsp;&nbsp;Length of Offering: | &nbsp;&nbsp;Shares will be offered on a continuous basis until either (1) the maximum number of Shares are sold; (2) 365 days from the date of qualification by the Commission; (3) the Company in its sole discretion extends the offering beyond 365 days from the date of qualification by the Commission, or (4) the Company in its sole discretion withdraws this Offering. |

---

**The Offering**

Common Stock Outstanding <sup>(1)</sup> 35,162,350 Shares <br> Common Stock in this Offering 5,000,000,000 Shares <br> Stock to be outstanding after the offering <sup>(2)</sup> 5,035,162,350 Shares

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)As of the date of this Offering Circular.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The total number of Shares of Common Stock assumes that the maximum number of Shares are sold in this Offering. The Company may not be able to sell the Maximum Offering Amount. The Company will conduct one or more closings on a rolling basis as funds are received from investors.

**Investment Analysis**

There is no assurance the Company will be profitable, or that management's opinion of the Company's future prospects will not be outweighed by the unanticipated losses, adverse regulatory developments and other risks. Investors should carefully consider the various risk factors below before investing in the Shares.

------

**RISK FACTORS**

The purchase of the Shares involves substantial risks. You should carefully consider the following risk factors in addition to any other risks associated with this investment. The Shares offered by the Company constitute a highly speculative investment and you should be in an economic position to lose your entire investment. The risks listed do not necessarily comprise all those associated with an investment in the Shares and are not set out in any particular order of priority. Additional risks and uncertainties may also have an adverse effect on the Company's business and your investment in the Shares. An investment in the Company may not be suitable for all recipients of this Offering Circular. You are advised to consult an independent professional adviser or attorney who specializes in investments of this kind before making any decision to invest. You should consider carefully whether an investment in the Company is suitable in the light of your personal circumstances and the financial resources available to you.

The discussions and information in this Offering Circular may contain both historical and forward- looking statements. To the extent that the Offering Circular contains forward-looking statements regarding the financial condition, operating results, business prospects, or any other aspect of the Company's business, please be advised that the Company's actual financial condition, operating results, and business performance may differ materially from that projected or estimated by the Company in forward-looking statements. The Company has attempted to identify, in context, certain of the factors it currently believes may cause actual future experience and results may differ from the Company's current expectations.

Before investing, you should carefully read and carefully consider the following risk factors:

**Risks Related to the Company and Its Business**

***We have a limited operating history.***

Our operating history is limited. There can be no assurance that our proposed plan of business can be realized in the manner contemplated and, if it cannot be, shareholders may lose all or a substantial part of their investment. There is no guarantee that we will ever realize any significant operating revenues or that our operations will ever be profitable.

***We are dependent upon management, key personnel, and consultants to execute our business plan.***

Our success is heavily dependent upon the continued active participation of our current management team, especially our current executive officer. Loss of this individual could have a material adverse effect upon our business, financial condition, or results of operations. Further, our success and the achievement of our growth plans depends on our ability to recruit, hire, train, and retain other highly qualified technical and managerial personnel. Competition for qualified employees among companies in our industry, and the loss of any of such persons, or an inability to attract, retain, and motivate any additional highly skilled employees required for the expansion of our activities, could have a materially adverse effect on our business. If we are unable to attract and retain the necessary personnel, consultants, and advisors, it could have a material adverse effect on our business, financial condition, or operations.

***Although we are dependent upon certain key personnel, we do not have any key man life insurance policies on any such people.***

We are dependent upon management in order to conduct our operations and execute our business plan; however, we have not purchased any insurance policies with respect to those individuals in the event of their death or disability. Therefore, should any of those key personnel, management, or founders die or become disabled, we will not receive any compensation that would assist with any such person's absence. The loss of any such person could negatively affect our business and operations.

***We are subject to income taxes as well as non-income-based taxes, such as payroll, sales, use, value-added, net worth, property, and goods and services taxes.***

Significant judgment is required in determining our provision for income taxes and other tax liabilities. In the ordinary course of our business, there are many transactions and calculations where the ultimate tax determination is uncertain. Although we believe that our tax estimates will be reasonable: (i) there is no assurance that the final determination of tax audits or tax disputes will not be different from what is reflected in our income tax provisions, expense amounts for non-income based taxes and accruals and (ii) any material differences could have an adverse effect on our financial position and results of operations in the period or periods for which determination is made.

------

***We are not subject to Sarbanes-Oxley regulation and lack the financial controls and safeguards required of public companies.***

We do not have the internal infrastructure necessary, and are not required to complete an attestation about our financial controls that would be required under Section 404 of the Sarbanes-Oxley Act of 2002. There can be no assurances that there are no significant deficiencies or material weaknesses in the quality of our financial controls. We expect to incur additional expenses and diversion of management's time if and when it becomes necessary to perform the system and process evaluation, testing, and remediation required in order to comply with the management certification and auditor attestation requirements.

***We have engaged in certain transactions with related persons.***

Please see the section of this offering circular entitled "Interest of Management and Others in Certain Transactions".

***Changes in employment laws or regulation could harm our performance.***

Various federal and state labor laws govern the Company's relationship with our employees and affect operating costs, including labor laws of non-USA jurisdictions, specifically Canadian federal and provincial statutes. These laws may include minimum wage requirements, overtime pay, healthcare reform and the implementation of various federal and state healthcare laws, unemployment tax rates, workers' compensation rates, citizenship requirements, union membership and sales taxes. A number of factors could adversely affect our operating results, including additional government-imposed increases in minimum wages, overtime pay, paid leaves of absence and mandated health benefits, mandated training for employees, changing regulations from the National Labor Relations Board and increased employee litigation including claims relating to the Fair Labor Standards Act.

***Our bank accounts will not be fully insured.***

The Company's regular bank accounts and the escrow account for this Offering each have federal insurance that is limited to a certain amount of coverage. It is anticipated that the account balances in each account may exceed those limits at times. In the event that any of the Company's banks should fail, we may not be able to recover all amounts deposited in these bank accounts.

***Our business plan is speculative.***

Our present business and planned business are speculative and subject to numerous risks and uncertainties. There is no assurance that the Company will generate significant revenues or profits.

***The Company will likely incur debt.***

The Company has incurred debt in the past and expects to incur future debt in order to fund operations. Complying with obligations under such indebtedness may have a material adverse effect on the Company and on your investment.

***Our expenses could increase without a corresponding increase in revenues.***

Our operating and other expenses could increase without a corresponding increase in revenues, which could have a material adverse effect on our financial results and on your investment. Factors which could increase operating and other expenses include, but are not limited to (1) increases in the rate of inflation, (2) increases in taxes and other statutory charges, (3) changes in laws, regulations or government policies which increase the costs of compliance with such laws, regulations or policies, (4) significant increases in insurance premiums, and (5) increases in borrowing costs.

***Increased costs could negatively affect our business.***

An increase in the cost of raw materials could affect the Company's profitability. Commodity and other price changes may result in unexpected increases in the cost of raw materials. To date, the sourcing and availability of raw materials has not been problematic and does not pose a significant risk to the Company, but the Company may be adversely affected by shortages of raw materials and/or an increase in their cost. In addition, energy cost increases could result in higher transportation, freight and other operating costs. We may not be able to increase our prices to offset these

------

increased costs without suffering reduced volume, sales and operating profit, and this could have an adverse effect on your investment.

***We may be unable to maintain or enhance our product image.***

It is important that we maintain and enhance the image of our existing and new products. The image and reputation of the Company's products may be impacted for various reasons, including litigation. Such concerns, even when unsubstantiated, could be harmful to the Company's image and the reputation of its products. From time to time, the Company may receive complaints from customers regarding products purchased from the Company. The Company may in the future receive correspondence from customers requesting reimbursement. Certain dissatisfied customers may threaten legal action against the Company if no reimbursement is made. The Company may become subject to product liability lawsuits from customers alleging injury because of a purported defect in products sold by the Company, claiming substantial damages and demanding payments from the Company. The Company is in the chain of title when it manufactures, supplies or distributes products, and therefore is subject to the risk of being held legally responsible for them. These claims may not be covered by the Company's insurance policies. Any resulting litigation could be costly for the Company, divert management attention, and could result in increased costs of doing business, or otherwise have a material adverse effect on the Company's business, results of operations, and financial condition. Any negative publicity generated as a result of customer complaints about the Company's products could damage the Company's reputation and diminish the value of the Company's brand, which could have a material adverse effect on the Company's business, results of operations, and financial condition, as well as your investment. Deterioration in the Company's brand equity (brand image, reputation and product quality) may have a material adverse effect on its financial results as well as your investment.

***If we are unable to protect our Intellectual Property effectively, we may be unable to operate our business.***

Our success will depend on our ability to obtain and maintain meaningful Intellectual Property Protection for any such Intellectual Property. The names and/or logos of Company brands (whether owned by the Company or licensed to us) may be challenged by holders of trademarks who file opposition notices, or otherwise contest trademark applications by the Company for its brands. Similarly, domains owned and used by the Company may be challenged by others who contest the ability of the Company to use the domain name or URL. Such challenges could have a material adverse effect on the Company's financial results as well as your investment.

***Computer, website, or information system breakdown could negatively affect our business.***

Computer, website and/or information system breakdowns as well as cyber security attacks could impair the Company's ability to service its customers leading to reduced revenue from sales and/or reputational damage, which could have a material adverse effect on the Company's financial results as well as your investment.

***Changes in the economy could have a detrimental impact on the Company.***

Changes in the general economic climate could have a detrimental impact on consumer expenditure and therefore on the Company's revenue. It is possible that recessionary pressures and other economic factors (such as declining incomes, future potential rising interest rates, higher unemployment and tax increases) may adversely affect customers' confidence and willingness to spend. Any of such events or occurrences could have a material adverse effect on the Company's financial results and on your investment.

***Additional financing may be necessary for the implementation of our growth strategy.***

The Company may require additional debt and/or equity financing to pursue our growth and business strategies. These include, but are not limited to enhancing our operating infrastructure and otherwise respond to competitive pressures. Given our limited operating history and existing losses, there can be no assurance that additional financing will be available, or, if available, that the terms will be acceptable to us. Lack of additional funding could force us to curtail substantially our growth plans. Furthermore, the issuance by us of any additional securities pursuant to any future fundraising activities undertaken by us would dilute the ownership of existing shareholders and may reduce the price of our Shares.

------

***Our operating plan relies in large part upon assumptions and analyses developed by the Company. If these assumptions or analyses prove to be incorrect, the Company's actual operating results may be materially different from our forecasted results.***

Whether actual operating results and business developments will be consistent with the Company's expectations and assumptions as reflected in its forecast depends on a number of factors, many of which are outside the Company's control, including, but not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·whether the Company can obtain sufficient capital to sustain and grow its business

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·our ability to manage the Company's growth

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·whether the Company can manage relationships with key vendors and advertisers

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·demand for the Company's products and services

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·the timing and costs of new and existing marketing and promotional efforts and/or competition

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·the Company's ability to retain existing key management, to integrate recent hires and to attract, retain and motivate qualified personnel

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·the overall strength and stability of domestic and international economies

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·consumer spending habits

Unfavorable changes in any of these or other factors, most of which are beyond the Company's control, could materially and adversely affect its business, results of operations and financial condition.

***Our operations may not be profitable.***

The Company may not be able to generate significant revenues in the future. In addition, we expect to incur substantial operating expenses in order to fund the expansion of our business. As a result, we may experience substantial negative cash flow for at least the foreseeable future and cannot predict when, or even if, the Company might become profitable.

***We may be unable to manage our growth or implement our expansion strategy.***

We may not be able to expand the Company's product and service offerings, the Company's markets, or implement the other features of our business strategy at the rate or to the extent presently planned. The Company's projected growth will place a significant strain on our administrative, operational and financial resources. If we are unable to successfully manage our future growth, establish and continue to upgrade our operating and financial control systems, recruit and hire necessary personnel or effectively manage unexpected expansion difficulties, our financial condition and results of operations could be materially and adversely affected.

***Our business model is evolving.***

Our business model is unproven and is likely to continue to evolve. Accordingly, our initial business model may not be successful and may need to be changed. Our ability to generate significant revenues will depend, in large part, on our ability to successfully market our products to potential users who may not be convinced of the need for our products and services or who may be reluctant to rely upon third parties to develop and provide these products. We intend to continue to develop our business model as the Company's market continues to evolve.

***Our employees may engage in misconduct or improper activities.***

The Company, like any business, is exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with laws or regulations, provide accurate information to regulators, comply with applicable standards, report financial information or data accurately or disclose unauthorized activities to the Company. In particular, sales, marketing and business arrangements are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve improper or illegal activities which could result in regulatory sanctions and serious harm to our reputation.

------

***Limitation on director liability.***

The Company may provide for the indemnification of directors to the fullest extent permitted by law and, to the extent permitted by such law, eliminate or limit the personal liability of directors to the Company and its shareholders for monetary damages for certain breaches of fiduciary duty. Such indemnification may be available for liabilities arising in connection with this Offering.

***Our success is dependent on our ability to attract and retain subscribers.***

The success of our business is dependent on our ability to attract and retain subscribers to our applications. We cannot be sure that we will be successful in attracting subscribers, or that we will be able to retain subscribers once they have downloaded our application. There are a number of factors that could prevent us from attracting or retaining subscribers, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Our failure to introduce features, products, or services that subscribers find engaging;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Harm to our brand and reputation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Pricing and perceived value of our applications;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Deteriorating general economic conditions or a change in consumer spending preferences or buying trends.

Failure to attract or maintain subscribers due to any of the above factors could have an adverse effect on our business, financial condition, and operating results.

***Cybersecurity risks could adversely affect our business and disrupt our operations.***

Threats to network and data security are increasingly diverse and sophisticated. Despite our efforts and processes to prevent breaches, our products and services, as well as our servers, computer systems, and those of third parties that we use in our operations are vulnerable to cybersecurity risks, including cyber-attacks such as viruses and worms, phishing attacks, ransomware or other extortion-based attacks, denial-of-service attacks, physical or electronic break-ins, third-party or employee theft or misuse, and similar disruptions from unauthorized tampering with our servers and computer systems or those of third parties that we use in our operations, which could lead to interruptions, delays, loss of critical data, unauthorized access to subscriber data, a negative impact on our application experience, and loss of consumer confidence. In addition, we may be the target of email scams that attempt to acquire personal data or company assets. Despite our efforts to create security barriers to such threats, we may not be able to entirely mitigate these risks. Any cyber-attack that attempts to obtain our or our subscribers' data and assets, disrupt our service, or otherwise access our systems, or those of third parties we use, if successful, could adversely affect our business, and financial condition and operating results, be expensive to remedy, and damage our reputation. In addition, any such breaches may result in negative publicity, and adversely affect our brand, impacting demand for our products and services, and could have an adverse effect on our business, financial condition, and operating results.

***The success of our applications depends upon effective operation with mobile device operating systems, networks, and standards that we do not control.***

Our success is depending on users being able to download and access our app, and there is no guarantee that popular mobile or desktop devices will support our app. We are dependent on the interoperability of our app with systems that we do not control, such as Android and iOS, and any changes in such systems that degrade the functionality of our app offering or give preferential treatment to competitors could adversely affect our platform's usage.

***We collect, store, process, and use personal data and other subscriber data, which subjects us to legal obligations and laws and regulations related to security and privacy, and any actual or perceived failure to meet those obligations could harm our business.***

We collect, process, store, and use a wide variety of data from current and prospective subscriber, including personal data (some of which is considered sensitive data under applicable laws), such as home addresses, and geolocation data. U.S. federal, state, and international laws and regulations governing privacy, data protection, and e-commerce transactions impose obligations on what we can do with our subscribers' personal data. These obligations include heightened transparency about data collection, use and sharing practices, new data privacy rights, and rules in respect to cross-border data transfers, which carry significant enforcement penalties for non-compliance. These laws and regulations also require us to safeguard our subscribers' personal data. Although we have established security measures, policies and procedures designed to protect subscriber information, ours or our third-party service

------

providers' security and testing measures may not prevent security breaches. Further, advances in computer capabilities, new discoveries in the field of cryptography, inadequate facility security, or other developments may result in a compromise or breach of the technology we use to protect subscriber data. Any compromise of our security or breach of our subscribers' privacy could harm our reputation or financial condition and, therefore, our business.

In addition, a party who circumvents our security measures or exploits inadequacies in our security measures, could, among other effects, misappropriate subscriber data or other proprietary information, cause interruptions in our operations, or expose subscriber to computer viruses or other disruptions. Actual or perceived vulnerabilities may lead to claims against us. To the extent that the measures we or our third-party business partners have taken prove to be insufficient or inadequate, we may become subject to litigation, breach notification obligations, or regulatory or administrative sanctions, which could result in significant fines, penalties, or damages and harm to our reputation. Depending on the nature of the information compromised, in the event of a data breach or other unauthorized access to our subscribers data, we may also have obligations to notify subscribers about the incident and we may need to provide some form of remedy, such as a subscription to a credit monitoring service, for the individuals affected by the incident. A growing number of legislative and regulatory bodies have adopted consumer notification requirements in the event of unauthorized access to or acquisition of certain types of personal data. Such breach notification laws continue to evolve and may be inconsistent from one jurisdiction to another, and there can be no assurances that we will be successful in our efforts to comply with these obligations. Complying with these obligations could cause us to incur substantial costs and could increase negative publicity surrounding any incident that compromises subscriber data.

Furthermore, we may legally be required to disclose personal data pursuant to demands from individuals, privacy advocates, regulators, government agencies, and law enforcement agencies in various jurisdictions with conflicting privacy and security laws. This disclosure or refusal to disclose personal data may result in a breach of privacy and data protection policies, notices, laws, rules, court orders, and regulations and could result in proceedings or actions against us in the same or other jurisdictions, damage to our reputation and brand, and inability to provide our products and services to consumers in certain jurisdictions. Additionally, new laws or regulations, or changes to or re-interpretations of the laws and regulations that govern our collection, use, and disclosure of subscriber data could impose additional requirements with respect to the retention and security of subscriber data, could limit our marketing activities, and have an adverse effect on our business, financial condition, and operating results.

Violations of applicable privacy laws or cybersecurity incidents could impact our business in a number of ways, such as a temporary suspension of some or all of our operating and/or information systems, damage our reputation, our relationships with customers, suppliers, vendors, and service providers and our brand and could result in lost data, lost sales, increased insurance premiums, substantial breach-notification and other remediation costs and lawsuits, as well as adversely affect results of operations. In addition, we may also face regulatory investigations with corresponding fines, civil claims including representative actions, and other class action type litigation (where individuals have suffered harm), potentially amounting to significant compensation or damages liabilities, as well as associated costs, diversion of internal resources, and reputational harm. We may also incur additional costs in the future related to the implementation of additional security measures to protect against new or enhanced data security and privacy threats, to comply with state, federal, and international laws that may be enacted to address personal data processing risks and data security threats, or to investigate or address potential or actual data security or privacy breaches.

------

**Risks Related to this Offering and Investment**

***We may undertake additional equity or debt financing that would dilute the shares in this offering.***

The Company may undertake further equity or debt financing, which may be dilutive to existing shareholders, including you, or result in an issuance of securities whose rights, preferences and privileges are senior to those of existing shareholders, including you, and also reducing the value of Shares subscribed for under this Offering.

***An investment in the Shares is speculative and there can be no assurance of any return on any such investment.***

An investment in the Company's Shares is speculative, and there is no assurance that investors will obtain any return on their investment. Investors will be subject to substantial risks involved in an investment in the Company, including the risk of losing their entire investment.

***The Shares are offered on a "Best Efforts" basis and we may not raise the Maximum Amount being offered.***

Since we are offering the Shares on a "best efforts" basis, there is no assurance that we will sell enough Shares to meet our capital needs. If you purchase Shares in this Offering, you will do so without any assurance that we will raise enough money to satisfy the full Use Of Proceeds To Issuer which we have outlined in this Offering Circular or to meet our working capital needs.

***If the maximum offering is not raised, it may increase the amount of long-term debt or the amount of additional equity we need to raise.***

There is no assurance that the maximum number of Shares in this Offering will be sold. If the maximum Offering amount is not sold, we may need to incur additional debt or raise additional equity in order to finance our operations. Increasing the amount of debt will increase our debt service obligations and make less cash available for distribution to our shareholders. Increasing the amount of additional equity that we will have to seek in the future will further dilute those investors participating in this Offering.

***We have not paid dividends in the past and do not expect to pay dividends in the future, so any return on investment may be limited to the value of our shares.***

We have never paid cash dividends on our Shares and do not anticipate paying cash dividends in the foreseeable future. The payment of dividends on our Shares will depend on earnings, financial condition and other business and economic factors affecting it at such time that management may consider relevant. If we do not pay dividends, our Shares may be less valuable because a return on your investment will only occur if its stock price appreciates.

***We may not be able to obtain additional financing.***

Even if we are successful in selling the maximum number of Shares in the Offering, we may require additional funds to continue and grow our business. We may not be able to obtain additional financing as needed, on acceptable terms, or at all, which would force us to delay our plans for growth and implementation of our strategy which could seriously harm our business, financial condition and results of operations. If we need additional funds, we may seek to obtain them primarily through additional equity or debt financings. Those additional financings could result in dilution to our current shareholders and to you if you invest in this Offering.

***The offering price has been arbitrarily determined.***

The offering price of the Shares has been arbitrarily established by us based upon our present and anticipated financing needs and bears no relationship to our present financial condition, assets, book value, projected earnings, or any other generally accepted valuation criteria. The offering price of the Shares may not be indicative of the value of the Shares or the Company, now or in the future.

------

***The management of the Company has broad discretion in application of proceeds.***

The management of the Company has broad discretion to adjust the application and allocation of the net proceeds of this offering in order to address changed circumstances and opportunities. As a result of the foregoing, our success will be substantially dependent upon the discretion and judgment of the management of the Company with respect to the application and allocation of the net proceeds hereof.

***An investment in our Shares could result in a loss of your entire investment.***

An investment in the Company's Shares offered in this Offering involves a high degree of risk and you should not purchase the Shares if you cannot afford the loss of your entire investment. You may not be able to liquidate your investment for any reason in the near future.

***There is no assurance that we will be able to pay dividends to our Shareholders.***

While we may choose to pay dividends at some point in the future to our shareholders, there can be no assurance that cash flow and profits will allow such distributions to ever be made.

***Sales of a substantial number of shares of our stock may cause the price of our stock to decline.***

If our shareholders sell substantial amounts of our Shares in the public market, Shares sold may cause the price to decrease below the current offering price. These sales may also make it more difficult for us to sell equity or equity related securities at a time and price that we deem reasonable or appropriate.

***We have made assumptions in our projections and in Forward-Looking Statements that may not be accurate.***

The discussions and information in this Offering Circular may contain both historical and "forward- looking statements" which can be identified by the use of forward-looking terminology including the terms "believes," "anticipates," "continues," "expects," "intends," "may," "will," "would," "should," or, in each case, their negative or other variations or comparable terminology. You should not place undue reliance on forward-looking statements. These forward-looking statements include matters that are not historical facts. Forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. Forward-looking statements contained in this Offering Circular, based on past trends or activities, should not be taken as a representation that such trends or activities will continue in the future. To the extent that the Offering Circular contains forward-looking statements regarding the financial condition, operating results, business prospects, or any other aspect of our business, please be advised that our actual financial condition, operating results, and business performance may differ materially from that projected or estimated by us. We have attempted to identify, in context, certain of the factors we currently believe may cause actual future experience and results to differ from our current expectations. The differences may be caused by a variety of factors, including but not limited to adverse economic conditions, lack of market acceptance, reduction of consumer demand, unexpected costs and operating deficits, lower sales and revenues than forecast, default on leases or other indebtedness, loss of suppliers, loss of supply, loss of distribution and service contracts, price increases for capital, supplies and materials, inadequate capital, inability to raise capital or financing, failure to obtain customers, loss of customers, the risk of litigation and administrative proceedings involving the Company or its employees, loss of government licenses and permits or failure to obtain them, higher than anticipated labor costs, the possible acquisition of new businesses or products that result in operating losses or that do not perform as anticipated, resulting in unanticipated losses, the possible fluctuation and volatility of the Company's operating results and financial condition, adverse publicity and news coverage, inability to carry out marketing and sales plans, loss of key executives, changes in interest rates, inflationary factors, and other specific risks that may be referred to in this Offering Circular or in other reports issued by us or by third-party publishers.

***You should be aware of the long-term nature of this investment.***

Because the Shares have not been registered under the Securities Act or under the securities laws of any state or non-United States jurisdiction, the Shares may have certain transfer restrictions. It is not currently contemplated that registration under the Securities Act or other securities laws will be effected. Limitations on the transfer of the Shares may also adversely affect the price that you might be able to obtain for the Shares in a private sale. You should be aware of the long-term nature of your investment in the Company. You will be required to represent that you are purchasing the Securities for your own account, for investment purposes and not with a view to resale or distribution thereof.

------

***The Shares in this Offering have no protective provisions.***

The Shares in this Offering have no protective provisions. As such, you will not be afforded protection by any provision of the Shares or as a Shareholder in the event of a transaction that may adversely affect you, including a reorganization, restructuring, merger or other similar transaction involving the Company. If there is a 'liquidation event' or 'change of control' the Shares being offered do not provide you with any protection. In addition, there are no provisions attached to the Shares in the Offering that would permit you to require the Company to repurchase the Shares in the event of a takeover, recapitalization or similar transaction.

***You will not have significant influence on the management of the Company.***

Substantially all decisions with respect to the management of the Company will be made exclusively by the officers, directors, managers or employees of the Company. You will have a very limited ability, if at all, to vote on issues of Company management and will not have the right or power to take part in the management of the Company and will not be represented on the board of directors or by managers of the Company. Furthermore, the holders of the Series A Preferred shares of the Company (currently John Morgan, CEO) control 60% of the vote on all matters requiring a shareholder vote by virtue of the Series A Preferred Stock Certificate of Designation. Accordingly, no person should purchase Shares unless he or she is willing to entrust all aspects of management to the Company and the holders of the Series A Preferred stock.

***There is no guarantee of any return on your investment.***

There is no assurance that you will realize a return on your investment or that you will not lose your entire investment. For this reason, you should read this Offering Circular and all exhibits and referenced materials carefully and should consult with your own attorney and business advisor prior to making any investment decision.

***Our Subscription Agreement identifies the state of Colorado for purposes of governing law.***

The Company's Subscription Agreement for shares issued under this Offering contains a choice of law provision stating, "all questions concerning the construction, validity, enforcement and interpretation of the Offering Circular, including, without limitation, this [Subscription] Agreement, shall be governed by and construed and enforced in accordance with the laws of the State of Colorado." As such, excepting matters arising under federal securities laws, any disputes arising between the Company and shareholders acquiring shares under this offering shall be determined in accordance with the laws of the state of Colorado. Furthermore, the Subscription Agreement establishes the state and federal courts located in Colorado as having jurisdiction over matters arising between the Company and shareholders.

These provisions may discourage shareholder lawsuits or limit shareholders' ability to obtain a favorable judicial forum in disputes with the Company and its directors, officers, or other employees.

IN ADDITION TO THE RISKS LISTED ABOVE, BUSINESSES ARE OFTEN SUBJECT TO RISKS NOT FORESEEN OR FULLY APPRECIATED BY THE MANAGEMENT. IT IS NOT POSSIBLE TO FORESEE ALL RISKS THAT MAY AFFECT THE COMPANY. MOREOVER, THE COMPANY CANNOT PREDICT WHETHER THE COMPANY WILL SUCCESSFULLY EFFECTUATE THE COMPANY'S CURRENT BUSINESS PLAN. EACH PROSPECTIVE PURCHASER IS ENCOURAGED TO CAREFULLY ANALYZE THE RISKS AND MERITS OF AN INVESTMENT IN THE SECURITIES AND SHOULD TAKE INTO CONSIDERATION WHEN MAKING SUCH ANALYSIS, AMONG OTHER FACTORS, THE RISK FACTORS DISCUSSED ABOVE.

------

**DETERMINATION OF OFFERING PRICE**

The Offering Price will be determined after qualification pursuant to Rule 253(b). The Offering Price will be arbitrarily determined and is not meant to reflect a valuation of the Company.

**DILUTION**

The term 'dilution' refers to the reduction (as a percentage of the aggregate Shares outstanding) that occurs for any given share of stock when additional Shares are issued. If all the Shares in this Offering are fully subscribed, sold, and converted, the Shares offered herein will constitute approximately 99% of the total Shares of common stock of the Company. The Company anticipates that, subsequent to this Offering, the Company may require additional capital and such capital may take the form of Common Stock, other stock or securities or debt convertible into stock. Such future fund raising will further dilute the percentage ownership of the Shares sold herein in the Company.

If you purchase shares in this Offering, your ownership interest in our Common Stock will be diluted immediately, to the extent of the difference between the price to the public charged for each share in this Offering and the net tangible book value per share of our Common Stock after this Offering.

Our historical net tangible book value as of June 30, 2022 was $(542,127). Historical net tangible book value equals the amount of our total tangible assets, less total liabilities, divided by the total number of shares of our Common Stock outstanding, all as of the date specified. Net tangible book value per share is an estimate based on the net tangible book value as of June 30, 2022 and 35,162,350 shares of common stock outstanding as of the date of this Offering Circular.

The following table illustrates the per share dilution to new investors discussed above, assuming the sale of, respectively, 100%, 75%, 50% and 25% of the Shares offered for sale in this Offering (before deducting our estimated offering expenses of $25,000):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**100%** | &nbsp;&nbsp;**75%** | &nbsp;&nbsp;**50%** | &nbsp;&nbsp;**25%** |
| &nbsp;&nbsp;**Funding Level** | $&nbsp;&nbsp;50000000 | $&nbsp;&nbsp;37500000 | $&nbsp;&nbsp;25000000 | $&nbsp;&nbsp;12500000 |
| &nbsp;&nbsp;Net tangible book value per share of Common Stock before this Offering<sup>(1)</sup> | $&nbsp;&nbsp;(0.015) | $&nbsp;&nbsp;(0.015) | $&nbsp;&nbsp;(0.015) | $&nbsp;&nbsp;(0.015) |
| &nbsp;&nbsp;Increase in net tangible book value per share attributable to new investors in this Offering | $&nbsp;&nbsp;0.025 | $&nbsp;&nbsp;0.025 | $&nbsp;&nbsp;0.025 | $&nbsp;&nbsp;0.024 |
| &nbsp;&nbsp;Net tangible book value per share of Common Stock, after this Offering | $&nbsp;&nbsp;0.010 | $&nbsp;&nbsp;0.010 | $&nbsp;&nbsp;0.010 | $&nbsp;&nbsp;0.009 |
| &nbsp;&nbsp;Economic Dilution per share to investors in the Offering | $&nbsp;&nbsp;0.0000 | $&nbsp;&nbsp;0.000 | $&nbsp;&nbsp;0.000 | $&nbsp;&nbsp;0.001 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Based on net tangible shareholders equity book value as of June 30, 2022 of $(542,127) and 35,162,350 outstanding shares of Common Stock as of the date of this Offering Circular.

There is no material disparity between the price of the Shares in this Offering and the effective cash cost to officers, directors, promoters and affiliated persons for shares acquired by them in a transaction during the past year, or that they have a right to acquire.

------

**PLAN OF DISTRIBUTION**

We are offering a Maximum Offering of up to $50,000,000 in Shares of our Common Stock. The offering is being conducted on a best-efforts basis without any minimum number of shares or amount of proceeds required to be sold. There is no minimum subscription amount required (other than a per investor minimum purchase) to distribute funds to the Company. The Company will not initially sell the Shares through commissioned broker-dealers, but may do so after the commencement of the offering. Any such arrangement will add to our expenses in connection with the offering. If we engage one or more commissioned sales agents or underwriters, we will supplement this Form 1-A/A to describe the arrangement. Subscribers have no right to a return of their funds. The Company may terminate the offering at any time for any reason at its sole discretion, and may extend the Offering past the termination date of 365 days from the date of qualification by the Commission in the absolute discretion of the Company and in accordance with the rules and provisions of Regulation A of the JOBS Act. None of the Shares being sold in this Offering are being sold by existing securities holders.

After the Offering Statement has been qualified by the Securities and Exchange Commission (the "SEC"), the Company will accept tenders of funds to purchase the Shares. No escrow agent is involved and the Company will receive the proceeds directly from any subscription. You will be required to complete a subscription agreement in order to invest.

All subscription agreements and checks received by the Company for the purchase of shares are irrevocable until accepted or rejected by the Company and should be delivered to the Company as provided in the subscription agreement. A subscription agreement executed by a subscriber is not binding on the Company until it is accepted on our behalf by the Company's Chief Executive Officer or by specific resolution of our board of directors. Any subscription not accepted within 30 days will be automatically deemed rejected. Once accepted, the Company will deliver a stock certificate to a purchaser within five days from request by the purchaser; otherwise, purchasers' shares will be noted and held on the book records of the Company.

The Company, by determination of the Board of Directors, in its sole discretion, may issue the Securities under this Offering for cash, promissory notes, services, and/or other consideration without notice to subscribers.

At this time no broker-dealer registered with the SEC and a member of the Financial Industry Regulatory Authority ("FINRA"), is being engaged as an underwriter or for any other purpose in connection with this Offering. This Offering will commence on the qualification of this Offering Circular, as determined by the Securities and Exchange Commission and continue for a period of 365 days. The Company may extend the Offering for an additional time period unless the Offering is completed or otherwise terminated by us, or unless we are required to terminate by application of Regulation A of the JOBS Act. Funds received from investors will be counted towards the Offering only if the form of payment, such as a check or wire transfer, clears the banking system and represents immediately available funds held by us prior to the termination of the subscription period, or prior to the termination of the extended subscription period if extended by the Company.

This is an offering made under "Tier 2" of Regulation A, and the shares will not be listed on a registered national securities exchange upon qualification. Therefore, the shares will be sold only to a person if the aggregate purchase price paid by such person is no more than 10% of the greater of such person's annual income or net worth, not including the value of his primary residence, as calculated under Rule 501 of Regulation D promulgated under Section 4(a)(2) of the Securities Act of 1933, as amended. In the case of sales to fiduciary accounts (Keogh Plans, Individual Retirement Accounts (IRAs) and Qualified Pension/Profit Sharing Plans or Trusts), the above suitability standards must be met by the fiduciary account, the beneficiary of the fiduciary account, or by the donor who directly or indirectly supplies the funds for the purchase of the shares. Investor suitability standards in certain states may be higher than those described in this Form 1-A/A and/or Offering Circular. These standards represent minimum suitability requirements for prospective investors, and the satisfaction of such standards does not necessarily mean that an investment in the Company is suitable for such persons. Different rules apply to accredited investors.

Each investor must represent in writing that he/she/it meets the applicable requirements set forth above and in the Subscription Agreement, including, among other things, that (i) he/she/it is purchasing the shares for his/her/its own account and (ii) he/she/it has such knowledge and experience in financial and business matters that he/she/it is capable of evaluating without outside assistance the merits and risks of investing in the shares, or he/she/it and his/her/its purchaser representative together have such knowledge and experience that they are capable of evaluating the merits and risks of investing in the shares. Broker-dealers and other persons participating in the offering must make a

------

reasonable inquiry in order to verify an investor's suitability for an investment in the Company. Transferees of the shares will be required to meet the above suitability standards.

The shares may not be offered, sold, transferred, or delivered, directly or indirectly, to any person who (i) is named on the list of "specially designated nationals" or "blocked persons" maintained by the U.S. Office of Foreign Assets Control ("OFAC") at www.ustreas.gov/offices/enforcement/ofac/sdn or as otherwise published from time to time, (ii) an agency of the government of a Sanctioned Country, (iii) an organization controlled by a Sanctioned Country, or (iv) is a person residing in a Sanctioned Country, to the extent subject to a sanctions program administered by OFAC. A "Sanctioned Country" means a country subject to a sanctions program identified on the list maintained by OFAC and available at www.ustreas.gov/offices/enforcement/ofac/sdn or as otherwise published from time to time. Furthermore, the shares may not be offered, sold, transferred, or delivered, directly or indirectly, to any person who (i) has more than fifteen percent (15%) of its assets in Sanctioned Countries or (ii) derives more than fifteen percent (15%) of its operating income from investments in, or transactions with, sanctioned persons or Sanctioned Countries.

**OTC Markets Considerations**

The OTC Markets is separate and distinct from the New York Stock Exchange and Nasdaq stock market or other national exchange. Neither the New York Stock Exchange nor Nasdaq has a business relationship with issuers of securities quoted on the OTC Markets. The SEC's order handling rules, which apply to New York Stock Exchange and Nasdaq-listed securities, do not apply to securities quoted on the OTC Markets.

Although other national stock markets have rigorous listing standards to ensure the high quality of their issuers and can delist issuers for not meeting those standards; the OTC Markets has no listing standards. Rather, it is the market maker who chooses to quote a security on the system, files the application, and is obligated to comply with keeping information about the issuer in its files.

Investors may have greater difficulty in getting orders filled than if we were on Nasdaq or other exchanges. Trading activity in general is not conducted as efficiently and effectively on OTC Markets as with exchange-listed securities. Also, because OTC Markets stocks are usually not followed by analysts, there may be lower trading volume than New York Stock Exchange and Nasdaq-listed securities.

**USE OF PROCEEDS TO ISSUER**

The Use of Proceeds is an estimate based on the Company's current business plan. We may find it necessary or advisable to reallocate portions of the net proceeds reserved for one category to another, or to add additional categories, and we will have broad discretion in doing so.

The maximum gross proceeds from the sale of the Shares in this Offering are $50,000,000 The net proceeds from the offering, assuming it is fully subscribed, are expected to be approximately $4,975,000 after the payment of offering costs such as printing, mailing, marketing, legal and accounting costs, and other compliance and professional fees that may be incurred. The estimate of the budget for offering costs is an estimate only and the actual offering costs may differ from those expected by management.

Management of the Company has wide latitude and discretion in the use of proceeds from this Offering. Ultimately, management of the Company intends to use substantially all of the net proceeds for general working capital and acquisitions. At present, management's best estimate of the use of proceeds, at various funding milestones, is set out in the chart below. However, potential investors should note that this chart contains only the best estimates of the Company's management based upon information available to them at the present time, and that the actual use of proceeds is likely to vary from this chart based upon circumstances as they exist in the future, various needs of the Company at different times in the future, and the discretion of the Company's management at all times.

A portion of the proceeds from this Offering may be used to compensate or otherwise make payments to officers or directors of the issuer. The officers and directors of the Company may be paid salaries and receive benefits that are commensurate with similar companies, and a portion of the proceeds may be used to pay these ongoing business expenses.

------

**USE OF PROCEEDS**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Offering Price: $20 Per Share**  | **10%** | **25%** | **50%** | **75%** | **100%** |
| Working Capital | $5000000  | $12500000 | $25000000 | $37500000 | $50000000 |
| Total | $5000000  | $12500000 | $25000000 | $37500000 | $50000000 |

---

The expected use of net proceeds from this Offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve and change. The amounts and timing of our actual expenditures, specifically with respect to working capital, may vary significantly depending on numerous factors. The precise amounts that we will devote to each of the foregoing items, and the timing of expenditures, will vary depending on numerous factors. As a result, our management will retain broad discretion over the allocation of the net proceeds from this Offering.

In the event we do not sell all the shares being offered, we may seek additional financing from other sources in order to support the intended use of proceeds indicated above. If we secure additional equity funding, investors in this Offering would be diluted. In all events, there can be no assurance that additional financing would be available to us when wanted or needed and, if available, on terms acceptable to us.

The allocation of the use of proceeds among the categories of anticipated expenditures represents management's best estimates based on the current status of the Company's proposed operations, plans, investment objectives, capital requirements, and financial conditions. No assurances can be provided that any milestone represented herein will be achieved. Future events, including changes in economic or competitive conditions of our business plan or the completion of less than the total Offering amount, may cause the Company to modify the above-described allocation of proceeds. The Company's use of proceeds may vary significantly in the event any of the Company's assumptions prove inaccurate. We reserve the right to change the allocation of net proceeds from the Offering as unanticipated events or opportunities arise. Additionally, the Company may from time to time need to raise more capital to address future needs.

**The Company reserves the right to change the use of proceeds set out herein based on the needs of the ongoing business of the Company and the discretion of the Company's management. The Company may reallocate the estimated use of proceeds among the various categories or for other uses if management deems such a reallocation to be appropriate.**

**DESCRIPTION OF BUSINESS**

**Corporate History**

Lee Pharmaceuticals, Inc., a Colorado corporation, was formed in April 1971, and, originally specialized in personal care products. From 2018 through 2021, the Company had no operations. Seeing no meaningful path forward for the Company in its previous state, on January 10, 2022, the Company's then CEO, Benjamin Berry, sold his 10 shares of Series A Preferred Stock to Accelerate Global Market Solutions Corp. ("AGMS") for $150,00 in cash, effecting a change of control. As part of this transaction, John Morgan was appointed the Company's new CEO. The strategic rationale for acquiring AGMS was the fact that the Company desired to exit its dormant status and viewed the acquisition of AGMS and its operations as an opportunity to do so. As a developer of mobile and PC based applications, the operating expenses of AGMS were relatively low, making AGMS an economically appealing target. Benjamin Berry, prior CEO of the Company, is a longtime acquaintance of John Morgan, the owner/operator of AGMS and current CEO of the Company. Post-acquisition, the Company is now seeking to develop services to be offered through applications to be used on PC and mobile devices. Our proposed plan of operations is included below.

**Subsidiaries**

None.

**Plan of Operations**

We want to be top of mind when clients think about new age secure technologies for this next stage of the global shared internet. We have evolved into an age of connectedness that requires a new set of rules for privacy and

------

authentication when interacting with others. We are working daily to be top of mind in this focused transition to an internet of everywhere.

We are currently focused on developing new applications to be used on PC and mobile devices. These applications will be offered through the Google Play Store and the Apple App Store. Our Green Living Lifestyle Nutrition App is the first of many applications we anticipate developing over the next few years. We estimate a cumulative total expense of approximately $50,000 per application in development costs and expenses per application.

Green Living Lifestyle Nutrition App

This application will encourage health and wellness through green options and alternative health strategies. There will be both a free and premium paid version of the app. The free version will have advertising placements targeted towards the user that will serve as a source of revenue for the Company. The paid version of the app will be an ad-free experience.

The development plan for the application is described in three phases below. Currently the app is under final development of Phase 1 and we are working to integrate users with profiles that allow them to utilize the app to have a strategy for their own personal health and wellness according to their body type, weight, and other elements related to their lifestyle and goals. Once Phase 1 is completed, the Company will move to Phases 2 and 3 below.

*Phase 1*

We anticipate that at the end of phase 1, users will be able to calculate their:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Body Mass Index

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Daily calorie requirements to lose/gain weight

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Target heart rate training zones

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Ideal weight

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Body fat percentage

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Blood volume

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Blood alcohol content

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Daily water intake requirements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Pregnancy Due Date

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Ovulation Period

*Phase 2*

Phase 2 will expand the app to include diet and workout plans, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Weight Loss Diet Plan

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Weight Gain Diet Plan

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Water Intake Tracker and Reminder

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Recipes containing high sirtuin foods and meal plans

*Phase 3*

Phase 3 will expand the diet and workout portion of the app as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Weight loss analysis

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Custom Diets and Meal Plans

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Daily Workout Notifications

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Exercise Tracker

We are a developer of health and fitness related mobile applications, but we are not a health care provider or health plan, nor are we developing our mobile applications on behalf of a health care provider, health plan, or any HIPAA covered entities. Our mobile applications are not intended for the use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment or prevention of disease, nor do our mobile applications require a prescription for access. As a result of the foregoing and based on guidance posted by the U.S. Department of Health & Human Services via www.hhs.gov, management is of the opinion that we are not considered a HIPAA covered entity and, thus, are not subject to HIPAA or other similar laws related to the storage of health information.

We value the cybersecurity of each user, and will include specific authentication features to help ensure that each users data and unique health information is kept private. Additionally, each user will be able to create a personal avatar in the app that they can use in lieu of uploading personal photos.

------

**Employees**

As of the date of this Offering Circular, the Company has 1 employee, including its officers, and he is full time. There is no collective agreement between the Company and its employees. The employment relationship between employees and the Company are individual and standard for the industry.

**Property**

Our corporate offices are located at 11 N Water Street Mobile, AL 36602. At this address, the Company occupies a modern shared-use office premises within reasonable proximity of management, consultants, and service providers.

**MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

**Fiscal Year End**

Previously, the Company's fiscal year end was September 30. On January 10, 2022, the Company's fiscal year end was changed to December 31. As such, we have included with this offering circular audited financial statements for the three month period ended December 31, 2021 and each of the years in the two-year period ended September 30, 2021.

**Forward-Looking Statements**

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words believes, project, expects, anticipates, estimates, intends, strategy, plan, may, will, would, will be, will continue, will likely result, and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

**Results of Operations** 

*Six months ended June 30, 2022 and 2021*

The Company had no revenues for the relevant periods.

For the six months ended June 30, 2022 and 2021, the Company had operating expenses of $205,513 and $0, respectively.

For the six months ended June 30, 2022 and 2021, the Company generated net losses of $205,513 and $0, respectively.

Liquidity and Capital Resources

Net cash used in operating activities was $192,342 and $0, respectively, for the six months ended June 30, 2022 and 2021.

There was no net cash provided by investing activities for the respective periods.

Net cash provided by financing activities was $205,510 and $0, respectively, for the six months ended June 30, 2022 and 2021.

As of June 30, 2021, the Company had $13,168 in cash to fund its operations.

------

*Three Months ended December 31, 2021 compared to years ended September 30, 2021 and 2020*

The Company had no revenues for the relevant periods.

The Company had operating expenses of $19,617 for the three months ended December 31, 2021, $3,930 for the year ended September 30, 2021 and $0 for the year ended September 30, 2020.

Net Income was $(19,617) for the three months ended December 31, 2021, $(3,930) for the year ended September 30, 2021, and $0 for the year ended September 30, 2020.

Liquidity and Capital Resources

The Company did not gain or use any cash in operating activities, investing activities, or financing activities for any of the relevant periods.

As of December 31, 2021, the Company had $0 in cash to fund its operations.

**Going Concern**

The financial statements attached to this Offering Circular have been prepared assuming that the company will continue as a going concern which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business. Additional financing is needed for the successful completion of the company's contemplated plan of operations and its transition, ultimately, to the attainment of profitable operations. The company's ability to raise additional equity or debt financing is unknown. An inability to resolve these factors would raise substantial doubts about the company's ability to continue as a going concern. These financial statements do not include any adjustments that may result from the outcome of the aforementioned uncertainties.

**Critical Accounting Policies**

The discussion and analysis of the Company's financial condition and results of operations are based upon the Company's condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. In consultation with the Company's Board of Directors, management has identified in the accompanying financial statements the accounting policies that it believes are key to an understanding of its financial statements. These are important accounting policies that require management's most difficult, subjective judgments.

**Recently Issued Accounting Pronouncements**

The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.

**Off-Balance Sheet Arrangements**

As of the date of this Offering Circular, there were no off-balance sheet arrangements.

**Subsequent Material Events**

The Company evaluated subsequent events that have occurred after the balance sheet date of June 30, 2021 and up through the date of this Offering Circular. There are two types of subsequent events: (i) recognized, or those that provide additional evidence with respect to conditions that existed at the date of the balance sheet, including the estimates inherent in the process of preparing financial statements, and (ii) non-recognized, or those that provide evidence with respect to conditions that did not exist at the date of the balance sheet but arose subsequent to that date. The Company has determined that there are no additional events that would require adjustment to or disclosure in the attached financial statements.

------

**DIRECTORS, EXECUTIVE OFFICERS AND SIGNIFICANT EMPLOYEES**

**Directors and Executive Officers**

The following table sets forth regarding our executive officers, directors and significant employees, including their ages as of the date of this Offering Circular:

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Position** | **Age** | **Director or Officer Since** |
| John Morgan | CEO, Director | 39 | January 2022 |

---

*Jonathan Morgan, CEO/Director*

John Morgan has held multiple positions and lead several public companies as CEO, President and Chairman over the last 10 years. After Receiving education from university of south Alabama and Columbia southern, as well as multiple certifications, John Morgan 39 yrs old, has been an Executive in the Telecommunications industry for over 16 years most Recently holding multiple executive positions and supporting roles in an ever changing communications industry for AT&T from June 2010 until present, supporting, training, influencing and managing thousands of employees both locally and nation wide over the course of his career for one of the fortune top 100 companies in the United States. John has extensive experience dealing with the Securities industry as an investor, former Finra Arbitrator and leading public companies through the murky waters of the Regulatory process. In the last 5 years John has also advised and held multiple officer and director positions with Resgreen Group, ZA Group, Nitches Inc and Lee Pharmaceuticals as well as advisor for several private companies in the Retail Space. John has been a board Member for Ronn Motor Group for approximately 6 months as member of the Compensation Committee..

**Board of Directors**

Our board of directors currently consists of one director, and he is not considered "independent" as defined in Rule 4200 of FINRA's listing standards. We may appoint additional independent directors to our board of directors in the future, particularly to serve on committees should they be established.

We have no formal policy regarding board diversity. In selecting board candidates, we seek individuals who will further the interests of our stockholders through an established record of professional accomplishment, the ability to contribute positively to our collaborative culture, knowledge of our business and understanding of our prospective markets.

**Committees of the Board of Directors**

We may establish an audit committee, compensation committee, a nominating and governance committee and other committees to our Board of Directors in the future, but have not done so as of the date of this Offering Circular. Until such committees are established, matters that would otherwise be addressed by such committees will be acted upon by the Board of Directors.

**Compensation of Directors and Executive Officers**

*Executive and Director Compensation*

We have no standard arrangement to compensate our directors for their services in their capacity. Directors are not paid for meetings attended. However, we intend to review and consider future proposals regarding board and executive compensation. All travel and lodging expenses associated with corporate matters are reimbursed by us, if and when incurred.

------

*Summary Compensation Table*

The following table represents information regarding the total compensation of our officers and directors for the years ended December 31, 2021 and 2020.

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name &**<br> **Principal Position** | **Fiscal**<br> **Year**<br> **ended**<br> **December 31,** | **Salary**<br> **($)** | **Bonus**<br> **($)** | **Stock**<br> **Awards**<br> **($)** | **Option**<br> **Awards($)** | **Non-Equity**<br> **Incentive Plan**<br> **Compensation**<br> **($)** | **Non-Qualified**<br> **Deferred**<br> **Compensation**<br> **Earnings ($)** | **All Other**<br> **Compensation**<br> **($)** | **Total**<br> **($)** |
| John Morgan,  | 2021 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CEO/Director | 2020 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

---

There are no other employment agreements between the Company and its executive officers or directors. Our executive officers and directors have the responsibility of determining the timing of remuneration programs for key personnel based upon such factors as positive cash flow, shares sales, product sales, estimated cash expenditures, accounts receivable, accounts payable, notes payable, and cash balances. At this time, management cannot accurately estimate when sufficient revenues will occur to implement this compensation, or the exact amount of compensation.

**Stock Incentive Plan; Options; Equity Awards**

We have not adopted any long-term incentive plan that provides compensation intended to serve as incentive for performance. None of our executive officers or directors received, nor do we have any arrangements to pay out, any bonus, stock awards, option awards, non-equity incentive plan compensation, or non-qualified deferred compensation

**Limitation of Liability and Indemnification of Officers and Directors**

Our Bylaws limit the liability of directors and officers of the Company to the maximum extent permitted by Colorado law. The Bylaws state that the Company shall indemnify and hold harmless each person who was or is a party or is threatened to be made a party to, or is otherwise involved in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such person is or was a director or an officer of the Company or such director or officer is or was serving at the request of the Company as a director, officer, partner, member, manager, trustee, employee or agent of another company or of a partnership, limited liability company, joint venture, trust or other enterprise.

The Company believes that indemnification under our Bylaws covers at least negligence and gross negligence on the part of indemnified parties. The Company also may secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in connection with their services to us, regardless of whether our Bylaws permit such indemnification.

The Company may also enter into separate indemnification agreements with its directors and officers, in addition to the indemnification provided for in our Bylaws. These agreements, among other things, may provide that we will indemnify our directors and officers for certain expenses (including attorneys' fees), judgments, fines and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of such person's services as one of our directors or officers, or rendering services at our request, to any of its subsidiaries or any other company or enterprise. We believe that these provisions and agreements are necessary to attract and retain qualified persons as directors and officers.

There is no pending litigation or proceeding involving any of our directors or officers as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification.

For additional information on indemnification and limitations on liability of our directors and officers, please review the Company's Bylaws, which are attached to this Offering Circular.

------

**SECURITY OWNERSHIP OF MANAGEMENT AND CERTAIN SECURITYHOLDERS**

The following table sets forth information regarding beneficial ownership of our Stock as of the date of this Offering Circular.

Beneficial ownership and percentage ownership are determined in accordance with the rules of the Securities and Exchange Commission and includes voting or investment power with respect to Shares of stock. This information does not necessarily indicate beneficial ownership for any other purpose.

Unless otherwise indicated and subject to applicable community property laws, to our knowledge, each Shareholder named in the following table possesses sole voting and investment power over their Shares of Stock. Percentage of beneficial ownership before the offering is based on 5,162,350 Shares of Common Stock outstanding and 10 shares of Series A Preferred Stock outstanding as of the date of this Offering Circular. Percentage of beneficial ownership after the Offering assumes the sale of the Maximum Offering Amount.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  | &nbsp;&nbsp;**Shares Beneficially Owned**<br> **Prior to Offering** | &nbsp;&nbsp;**Shares Beneficially Owned**<br> **Prior to Offering** | &nbsp;&nbsp;**Shares Beneficially Owned**<br> **After Offering** | &nbsp;&nbsp;**Shares Beneficially Owned**<br> **After Offering** |
| &nbsp;&nbsp;**Name and Position** | &nbsp;&nbsp;**Class** | &nbsp;&nbsp;**Number** | &nbsp;&nbsp;**Percent** | &nbsp;&nbsp;**Number** | &nbsp;&nbsp;**Percent** |
| &nbsp;&nbsp;John Morgan, | &nbsp;&nbsp;Common | &nbsp;&nbsp;- | &nbsp;&nbsp;- | &nbsp;&nbsp;- | &nbsp;&nbsp;- |
| &nbsp;&nbsp;CEO/Director<sup>(1)</sup> | &nbsp;&nbsp;Series A Preferred | &nbsp;&nbsp;10 | &nbsp;&nbsp;100% | &nbsp;&nbsp;10 | &nbsp;&nbsp;100% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.Includes shares held by Accelerate Global Market Solutions, of which John Morgan is a control person.

**INTEREST OF MANAGEMENT AND OTHERS IN CERTAIN TRANSACTIONS**

During the last two full fiscal years and the current fiscal year, there are no transactions or proposed transactions involving the Company and a related party, in which the amount involved exceeds the lesser of $120,000 or one percent of the average of the Company's total assets at year-end for its last three fiscal years.

**DESCRIPTION OF SECURITIES**

**Common Stock**

The Company is authorized to issue 6,000,000,000 shares of Common Stock. The holders of our common stock are entitled to one vote per share on all matters submitted to a vote of our stockholders. The holders of the common stock have the sole right to vote, except as otherwise provided by law, by our articles of incorporation, or in a statement by our board of directors in a Preferred Stock Designation.

In addition, such holders are entitled to receive ratably such dividends, if any, as may be declared from time to time by our board of directors out of legally available funds, subject to the payment of preferential dividends or other restrictions on dividends contained in any Preferred Stock Designation, including, without limitation, the Preferred Stock Designation establishing a series of preferred stock described above. In the event of the dissolution, liquidation or winding up of Lee Pharmaceuticals, Inc., the holders of our common stock are entitled to share ratably in all assets remaining after payment of all our liabilities, subject to the preferential distribution rights granted to the holders of any series of our preferred stock in any Preferred Stock Designation, including, without limitation, the Preferred Stock Designation establishing a series of our preferred stock described above.

The holders of the common stock do not have cumulative voting rights or preemptive rights to acquire or subscribe for additional, unissued or treasury shares in accordance with the laws of the State of Colorado. Accordingly, excluding any voting rights granted to any series of our preferred stock, the holders of more than 50 percent of the issued and outstanding shares of the common stock voting for the election of directors can elect all of the directors if they choose to do so, and in such event, the holders of the remaining shares of the common stock voting for the election of the directors will be unable to elect any person or persons to the board of directors. All outstanding shares of the common stock are fully paid and nonassessable.

The laws of the State of Colorado provide that the affirmative vote of a majority of the holders of the outstanding shares of our common stock and any series of our preferred stock entitled to vote thereon is required to authorize any amendment to our articles of incorporation, any merger or consolidation of Lee Pharmaceuticals, Inc. with any corporation, or any liquidation or disposition of any substantial assets of Lee Pharmaceuticals, Inc.

------

**Series A Preferred Stock**

The Company is authorized to issue 10 shares of Series A Preferred Stock, with a par value of $0.001 per share. As of the date of this Offering Circular, the Company had 10 shares of Series A Preferred Stock outstanding. Pursuant to the Series A Certificate of Designation ("COD"), holders of the Series A Preferred Stock vote together with other holders of the Company's preferred stock and common stock as a single class. The COD further states the "Series A Preferred Stock stockholder is entitled to 60% of all votes with respect to any and all matters presented to the stockholders of the Company for their action or consideration." Functionally, this means the 10 shares of Series A Preferred Stock shall be allocated 60% of the shareholder votes on a fully diluted basis. For example, if the Company had 40,000,000 shares of Common stock issued and outstanding and 10 shares of Series A Preferred issued and outstanding, the Series A shareholders would be entitled to 60,000,000 votes. As a formula, this reads as follows:

*(Total Common stock issued and outstanding/40%) x 60% = Number of votes allocated to Series A shareholders.*

In the event of a partial transfer of the Series A Preferred stock, each Series A shareholder would be entitled to vote his/her shares on a pro rata basis. For example, if Mr. Morgan sold, assigned, or transferred three Series A shares to a new shareholder, Mr. Morgan's seven remaining shares would account for 42% of the overall shareholder vote (60% x .7 = 42%) and the new shareholder's three shares would account for 18% of the overall shareholder vote.

**SECURITIES BEING OFFERED**

The Company is offering shares of Common Stock. Except as otherwise required by law, the Company's Articles of Incorporation or Bylaws, each Shareholder shall be entitled to one vote for each Share held by such Shareholder on the record date of any vote of Shareholders of the Company. The Shares of Common Stock, when issued, will be fully paid and non-assessable.

The Company does not expect to create any additional classes of Common Stock during the next 12 months, but the Company is not limited from creating additional classes which may have preferred dividend, voting and/or liquidation rights or other benefits not available to holders of its common stock.

The Company does not expect to declare dividends for shareholders in the foreseeable future. Dividends will be declared, if at all (and subject to rights of holders of additional classes of securities, if any), in the discretion of the Company's Board of Directors. Dividends, if ever declared, may be paid in cash, in property, or in shares of the capital stock of the Company, subject to the provisions of law, the Company's Bylaws and the Certificate of Incorporation. Before payment of any dividend, there may be set aside out of any funds of the Company available for dividends such sums as the Board of Directors, in its absolute discretion, deems proper as a reserve for working capital, to meet contingencies, for equalizing dividends, for repairing or maintaining any property of the Company, or for such other purposes as the Board of Directors shall deem in the best interests of the Company.

Because this is a best-efforts offering, there is no minimum number of Shares that needs to be sold in order for funds to be released to the Company and for this Offering to hold its first closing.

The minimum subscription that will be accepted from an investor $1,000 (the 'Minimum Subscription').

A subscription for $1,000 or more in the Shares may be made only by tendering to the Company the executed Subscription Agreement (electronically or in writing) delivered with the subscription price in a form acceptable to the Company, via check, wire, credit or debit card, or ACH. The execution and tender of the documents required, as detailed in the materials, constitutes a binding offer to purchase the number of Shares stipulated therein and an agreement to hold the offer open until the Expiration Date or until the offer is accepted or rejected by the Company, whichever occurs first.

The Company reserves the unqualified discretionary right to reject any subscription for Shares, in whole or in part. The Company reserves the unqualified discretionary right to accept any subscription for Shares, in an amount less than the Minimum Subscription. If the Company rejects any offer to subscribe for the Shares, it will return the subscription payment, without interest or reduction. The Company's acceptance of your subscription will be effective when an authorized representative of the Company issues you written or electronic notification that the subscription was accepted.

------

Excepting matters arising under federal securities laws, any disputes between the Company and shareholders shall be governed in reliance on the laws of the state of Colorado. Furthermore, the Subscription Agreement for this Regulation A offering appoints the state and federal courts located in the state of Colorado as having jurisdiction over any disputes related to this Regulation A offering between the Company and shareholders.

**Transfer Agent**

Our transfer agent is Issuer Direct Corporation, One Glenwood Avenue, Suite 1001 Raleigh, NC 27603. The transfer agent is registered under the Exchange Act and operates under the regulatory authority of the SEC and FINRA.

**DISQUALIFYING EVENTS DISCLOSURE**

Recent changes to Regulation A promulgated under the Securities Act prohibit an issuer from claiming an exemption from registration of its securities under such rule if the issuer, any of its predecessors, any affiliated issuer, any director, executive officer, other officer participating in the offering of the interests, general partner or managing member of the issuer, any beneficial owner of 20% or more of the voting power of the issuer's outstanding voting equity securities, any promoter connected with the issuer in any capacity as of the date hereof, any investment manager of the issuer, any person that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with such sale of the issuer's interests, any general partner or managing member of any such investment manager or solicitor, or any director, executive officer or other officer participating in the offering of any such investment manager or solicitor or general partner or managing member of such investment manager or solicitor has been subject to certain "Disqualifying Events" described in Rule 506(d)(1) of Regulation D subsequent to September 23, 2013, subject to certain limited exceptions. The Company is required to exercise reasonable care in conducting an inquiry to determine whether any such persons have been subject to such Disqualifying Events and is required to disclose any Disqualifying Events that occurred prior to September 23, 2013 to investors in the Company. The Company believes that it has exercised reasonable care in conducting an inquiry into Disqualifying Events by the foregoing persons and is aware of the no such Disqualifying Events.

It is possible that (a) Disqualifying Events may exist of which the Company is not aware and (b) the SEC, a court or other finder of fact may determine that the steps that the Company has taken to conduct its inquiry were inadequate and did not constitute reasonable care. If such a finding were made, the Company may lose its ability to rely upon exemptions under Regulation A, and, depending on the circumstances, may be required to register the Offering of the Company's Common Stock with the SEC and under applicable state securities laws or to conduct a rescission offer with respect to the securities sold in the Offering.

**ERISA CONSIDERATIONS**

Trustees and other fiduciaries of qualified retirement plans or IRAs that are set up as part of a plan sponsored and maintained by an employer, as well as trustees and fiduciaries of Keogh Plans under which employees, in addition to self-employed individuals, are participants (together, "ERISA Plans"), are governed by the fiduciary responsibility provisions of Title 1 of the Employee Retirement Income Security Act of 1974 ("ERISA"). An investment in the Shares by an ERISA Plan must be made in accordance with the general obligation of fiduciaries under ERISA to discharge their duties (i) for the exclusive purpose of providing benefits to participants and their beneficiaries; (ii) with the same standard of care that would be exercised by a prudent man familiar with such matters acting under similar circumstances; (iii) in such a manner as to diversify the investments of the plan, unless it is clearly prudent not do so; and (iv) in accordance with the documents establishing the plan. Fiduciaries considering an investment in the Shares should accordingly consult their own legal advisors if they have any concern as to whether the investment would be inconsistent with any of these criteria.

Fiduciaries of certain ERISA Plans which provide for individual accounts (for example, those which qualify under Section 401(k) of the Code, Keogh Plans and IRAs) and which permit a beneficiary to exercise independent control over the assets in his individual account, will not be liable for any investment loss or for any breach of the prudence or diversification obligations which results from the exercise of such control by the beneficiary, nor will the beneficiary be deemed to be a fiduciary subject to the general fiduciary obligations merely by virtue of his exercise of such control. On October 13, 1992, the Department of Labor issued regulations establishing criteria for determining whether the extent of a beneficiary's independent control over the assets in his account is adequate to relieve the ERISA Plan's fiduciaries of their obligations with respect to an investment directed by the beneficiary. Under the regulations, the beneficiary must not only exercise actual, independent control in directing the particular investment

------

transaction, but also the ERISA Plan must give the participant or beneficiary a reasonable opportunity to exercise such control, and must permit him to choose among a broad range of investment alternatives.

Trustees and other fiduciaries making the investment decision for any qualified retirement plan, IRA or Keogh Plan (or beneficiaries exercising control over their individual accounts) should also consider the application of the prohibited transactions provisions of ERISA and the Code in making their investment decision. Sales and certain other transactions between a qualified retirement plan, IRA or Keogh Plan and certain persons related to it (*e.g.,* a plan sponsor, fiduciary, or service provider) are prohibited transactions. The particular facts concerning the sponsorship, operations and other investments of a qualified retirement plan, IRA or Keogh Plan may cause a wide range of persons to be treated as parties in interest or disqualified persons with respect to it. Any fiduciary, participant or beneficiary considering an investment in Shares by a qualified retirement plan IRA or Keogh Plan should examine the individual circumstances of that plan to determine that the investment will not be a prohibited transaction. Fiduciaries, participants or beneficiaries considering an investment in the Shares should consult their own legal advisors if they have any concern as to whether the investment would be a prohibited transaction.

Regulations issued on November 13, 1986, by the Department of Labor (the "Final Plan Assets Regulations") provide that when an ERISA Plan or any other plan covered by Code Section 4975 (*e.g.*, an IRA or a Keogh Plan which covers only self-employed persons) makes an investment in an equity interest of an entity that is neither a "publicly offered security" nor a security issued by an investment company registered under the Investment Company Act of 1940, the underlying assets of the entity in which the investment is made could be treated as assets of the investing plan (referred to in ERISA as "plan assets"). Programs which are deemed to be operating companies or which do not issue more than 25% of their equity interests to ERISA Plans are exempt from being designated as holding "plan assets." Management anticipates that we would clearly be characterized as "operating" for the purposes of the regulations, and that it would therefore not be deemed to be holding "plan assets."

Classification of our assets as "plan assets" could adversely affect both the plan fiduciary and management. The term "fiduciary" is defined generally to include any person who exercises any authority or control over the management or disposition of plan assets. Thus, classification of our assets as plan assets could make the management a "fiduciary" of an investing plan. If our assets are deemed to be plan assets of investor plans, transactions which may occur in the course of its operations may constitute violations by the management of fiduciary duties under ERISA. Violation of fiduciary duties by management could result in liability not only for management but also for the trustee or other fiduciary of an investing ERISA Plan. In addition, if our assets are classified as "plan assets," certain transactions that we might enter into in the ordinary course of our business might constitute "prohibited transactions" under ERISA and the Code.

Under Code Section 408(i), as amended by the Tax Reform Act of 1986, IRA trustees must report the fair market value of investments to IRA holders by January 31 of each year. The Service has not yet promulgated regulations defining appropriate methods for the determination of fair market value for this purpose. In addition, the assets of an ERISA Plan or Keogh Plan must be valued at their "current value" as of the close of the plan's fiscal year in order to comply with certain reporting obligations under ERISA and the Code. For purposes of such requirements, "current value" means fair market value where available. Otherwise, current value means the fair value as determined in good faith under the terms of the plan by a trustee or other named fiduciary, assuming an orderly liquidation at the time of the determination. We do not have an obligation under ERISA or the Code with respect to such reports or valuation although management will use good faith efforts to assist fiduciaries with their valuation reports. There can be no assurance, however, that any value so established (i) could or will actually be realized by the IRA, ERISA Plan or Keogh Plan upon sale of the Shares or upon liquidation of us, or (ii) will comply with the ERISA or Code requirements.

The income earned by a qualified pension, profit sharing or stock bonus plan (collectively, "Qualified Plan") and by an individual retirement account ("IRA") is generally exempt from taxation. However, if a Qualified Plan or IRA earns "unrelated business taxable income" ("UBTI"), this income will be subject to tax to the extent it exceeds $1,000 during any fiscal year. The amount of unrelated business taxable income in excess of $1,000 in any fiscal year will be taxed at rates up to 36%. In addition, such unrelated business taxable income may result in a tax preference, which may be subject to the alternative minimum tax. It is anticipated that income and gain from an investment in the Shares will not be taxed as UBTI to tax exempt shareholders, because they are participating only as passive financing sources.

------

**DIVIDEND POLICY**

Subject to preferences that may be applicable to any then-outstanding shares of Preferred Stock, if any, and any other restrictions, holders of Common Stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. We and our predecessors have not declared any dividends in the past. Further, we do not presently contemplate that there will be any future payment of any dividends on Common Stock.

**SHARES ELIGIBLE FOR FUTURE SALE**

Prior to this Offering, there has been a limited market for our Common Stock on the OTC Markets. Future sales of substantial amounts of our Common Stock, or securities or instruments convertible into our Common Stock, in the public market, or the perception that such sales may occur, could adversely affect the market price of our Common Stock prevailing from time to time. Furthermore, because there will be limits on the number of shares available for resale shortly after this Offering due to contractual and legal restrictions described below, there may be resales of substantial amounts of our Common Stock in the public market after those restrictions lapse. This could adversely affect the market price of our Common Stock prevailing at that time.

Upon completion of this Offering, assuming the maximum amount of shares of Common Stock offered in this Offering are sold, there will be 5,035,162,350 shares of our Common Stock outstanding.

**Rule 144**

In general, a person who has beneficially owned restricted shares of our Common Stock for at least twelve months, in the event we are a reporting company under Regulation A, or at least six months, in the event we have been a reporting company under the Exchange Act for at least 90 days before the sale, would be entitled to sell such securities, provided that such person is not deemed to be an affiliate of ours at the time of sale or to have been an affiliate of ours at any time during the 90 days preceding the sale. A person who is an affiliate of ours at such time would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of shares that does not exceed the greater of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·1% of the number of shares of our Common Stock then outstanding; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·the average weekly trading volume of our Common Stock during the four calendar weeks preceding the filing by such person of a notice on Form 144 with respect to the sale;

provided that, in each case, we are subject to the periodic reporting requirements of the Exchange Act for at least 90 days before the sale. Rule 144 trades must also comply with the manner of sale, notice and other provisions of Rule 144, to the extent applicable.

**INVESTOR ELIGIBILITY STANDARDS & ADDITIONAL INFORMATION ABOUT THE OFFERING**

**Investment Limitations**

Generally, no sale may be made to you in this Offering if the aggregate purchase price you pay is more than 10% of the greater of your annual income or net worth (please see below on how to calculate your net worth). Different rules apply to accredited investors and non-natural persons. Before making any representation that your investment does not exceed applicable thresholds, we encourage you to review Rule 251(d)(2)(i)(C) of Regulation A+. For general information on investing, we encourage you to refer to www.investor.gov.

Because this is a Tier 2, Regulation A+ offering, most investors must comply with the 10% limitation on investment in the Offering. The only investor in this Offering exempt from this limitation is an "accredited investor" as defined under Rule 501 of Regulation D under the Securities Act. If you meet one of the following tests you should qualify as an accredited investor:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)You are a natural person who has had individual income in excess of $200,000 in each of the two most recent years, or joint income with your spouse in excess of $300,000 in each of these years, and have a reasonable expectation of reaching the same income level in the current year;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)You are a natural person and your individual net worth, or joint net worth with your spouse, exceeds $1,000,000 at the time you purchase Shares (please see below on how to calculate your net worth);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)You are an executive officer or general partner of the issuer or a manager or executive officer of the general partner of the issuer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)You are an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, or the Code, a corporation, a Massachusetts or similar business trust or a partnership, not formed for the specific purpose of acquiring the Shares, with total assets in excess of $5,000,000;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)You are a bank or a savings and loan association or other institution as defined in the Securities Act, a broker or dealer registered pursuant to Section 15 of the Exchange Act, an insurance company as defined by the Securities Act, an investment company registered under the Investment Company Act of 1940 (Investment Company Act), or a business development company as defined in that act, any Small Business Investment Company licensed by the Small Business Investment Act of 1958 or a private business development company as defined in the Investment Advisers Act of 1940;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)You are an entity (including an Individual Retirement Account trust) in which each equity owner is an accredited investor;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)You are a trust with total assets in excess of $5,000,000, your purchase of Shares is directed by a person who either alone or with his purchaser representative(s) (as defined in Regulation D promulgated under the Securities Act) has such knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks of the prospective investment, and you were not formed for the specific purpose of investing in the Shares; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii)You are a plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has assets in excess of $5,000,000.

**Offering Period and Expiration Date**

This Offering will start on the date on which the SEC initially qualifies this Offering Statement (the Qualification Date) and will terminate on the Termination Date.

**Procedures for Subscribing**

If you decide to subscribe for the Shares in this Offering, you should:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.Electronically receive, review, execute and deliver to us a Subscription Agreement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Deliver funds directly to the Company's designated bank account via bank wire transfer (pursuant to the wire transfer instructions set forth in our Subscription Agreement) or electronic funds transfer via wire transfer.

Any potential investor will have ample time to review the subscription agreement, along with their counsel, prior to making any final investment decision. We shall only deliver such subscription agreement upon request after a potential investor has had ample opportunity to review this Offering Circular.

*Right to Reject Subscriptions*. After we receive your complete, executed subscription agreement and the funds required under the subscription agreement have been transferred to our designated account, we have the right to review and accept or reject your subscription in whole or in part, for any reason or for no reason. We will return all monies from rejected subscriptions immediately to you, without interest or deduction.

*Acceptance of Subscriptions*. Upon our acceptance of a subscription agreement, we will countersign the subscription agreement and issue the shares subscribed at closing. Once you submit the subscription agreement, you may not revoke or change your subscription or request your subscription funds. All submitted subscription agreements are irrevocable.

Under Rule 251 of Regulation A+, non-accredited, non-natural investors are subject to the investment limitation and may only invest funds which do not exceed 10% of the greater of the purchaser's revenue or net assets (as of the

------

purchaser's most recent fiscal year end). A non-accredited, natural person may only invest funds which do not exceed 10% of the greater of the purchaser's annual income or net worth (please see below on how to calculate your net worth).

**NOTE**: For the purposes of calculating your net worth, it is defined as the difference between total assets and total liabilities. This calculation must exclude the value of your primary residence and may exclude any indebtedness secured by your primary residence (up to an amount equal to the value of your primary residence). In the case of fiduciary accounts, net worth and/or income suitability requirements may be satisfied by the beneficiary of the account or by the fiduciary, if the fiduciary directly or indirectly provides funds for the purchase of the Shares.

In order to purchase the Shares and prior to the acceptance of any funds from an investor, an investor will be required to represent, to the Company's satisfaction, that such investor is either an accredited investor or is in compliance with the 10% of net worth or annual income limitation on investment in this Offering.

**LEGAL MATTERS**

Certain legal matters with respect to the Shares offered hereby will be passed upon by Jeff Turner, JDT Legal, PLLC.

**REPORTS**

Following this Tier 2, Regulation A offering, we will be required to comply with certain ongoing disclosure requirements under Rule 257 of Regulation A, in addition to our reporting requirements under the OTC Pink Basic Disclosure Guidelines.

**WHERE YOU CAN FIND MORE INFORMATION**

We have filed with the SEC a Regulation A Offering Statement on Form 1-A/A under the Securities Act with respect to the shares of Common Stock offered hereby. This Offering Circular, which constitutes a part of the Offering Statement, does not contain all of the information set forth in the Offering Statement or the exhibits and schedules filed therewith. For further information about us and the Common Stock offered hereby, we refer you to the Offering Statement and the exhibits and schedules filed therewith. Statements contained in this Offering Circular regarding the contents of any contract or other document that is filed as an exhibit to the Offering Statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the Offering Statement. Upon the completion of this Offering, we will be required to file periodic reports, proxy statements, and other information with the SEC pursuant to the Securities Exchange Act of 1934. You may read and copy this information at the SEC's Public Reference Room, 100 F Street, N.E., Room 1580, Washington, D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains an Internet website that contains reports, proxy statements and other information about issuers, including us, that file electronically with the SEC. The address of this site is www.sec.gov.

------

**SIGNATURES**

Pursuant to the requirements of Regulation A, the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form 1-A/A and has duly caused this Offering statement to be signed on its behalf by the undersigned, thereunto duly authorized, on January 19, 2023.

**Lee Pharmaceuticals, Inc.**

By: */s/ John Morgan*

John Morgan

CEO

January 19, 2023

This Offering statement has been signed by the following persons in the capacities and on the dates indicated.

By: */s/ John Morgan*

John Morgan

Principal Executive Officer, Principal Financial Officer, Sole Director

January 19, 2023

**ACKNOWLEDGEMENT ADOPTING TYPED SIGNATURES**

The undersigned hereby authenticate, acknowledge, and otherwise adopt the typed signatures above and as otherwise appear in this filing and Offering.

By: */s/ John Morgan*

John Morgan

CEO

January 19, 2023

------

**PART III: EXHIBITS**

**Index to Exhibits**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  |  | &nbsp;&nbsp;**Incorporated by Reference** | &nbsp;&nbsp;**Incorporated by Reference** |
| &nbsp;&nbsp;**Exhibit**<br> **No.** | &nbsp;&nbsp;**Description** | &nbsp;&nbsp;**Filed**<br> **Herewith**<br> **(\*)** | &nbsp;&nbsp;**Filing**<br> **Type** | &nbsp;&nbsp;**Date**<br> **Filed** |
| &nbsp;&nbsp;[2.1](http://www.sec.gov/Archives/edgar/data/58411/000139390522000358/lphm_ex21.htm) | &nbsp;&nbsp;Articles of Incorporation |  | &nbsp;&nbsp;1-A | &nbsp;&nbsp;09/13/2022 |
| &nbsp;&nbsp;[2.2](http://www.sec.gov/Archives/edgar/data/58411/000139390522000358/lphm_ex22.htm) | &nbsp;&nbsp;Bylaws |  | &nbsp;&nbsp;1-A | &nbsp;&nbsp;09/13/2022 |
| &nbsp;&nbsp;[2.3](http://www.sec.gov/Archives/edgar/data/58411/000139390522000358/lphm_ex23.htm) | &nbsp;&nbsp;Amendment to Articles of Incorporation |  | &nbsp;&nbsp;1-A | &nbsp;&nbsp;09/13/2022 |
| &nbsp;&nbsp;[4.1](http://www.sec.gov/Archives/edgar/data/58411/000139390522000358/lphm_ex41.htm) | &nbsp;&nbsp;Subscription Agreement |  | &nbsp;&nbsp;1-A | &nbsp;&nbsp;09/13/2022 |
| &nbsp;&nbsp;[1](http://www.sec.gov/Archives/edgar/data/58411/000139390522000423/lphm_ex111.htm)[1](http://www.sec.gov/Archives/edgar/data/58411/000139390522000423/lphm_ex111.htm)[.1](http://www.sec.gov/Archives/edgar/data/58411/000139390522000423/lphm_ex111.htm) | &nbsp;&nbsp;Auditor's Consent |  | &nbsp;&nbsp;1-A | &nbsp;&nbsp;10/18/2022 |
| &nbsp;&nbsp;[12.1](http://www.sec.gov/Archives/edgar/data/58411/000139390522000358/lphm_ex121.htm) | &nbsp;&nbsp;Legal Opinion and Consent |  | &nbsp;&nbsp;1-A | &nbsp;&nbsp;09/13/2022 |

---

------

**PART F/S: FINANCIAL STATEMENTS**

**LEE PHARMACEUTICALS, INC.**

**INDEX TO FINANCIAL STATEMENTS**

**Financial Statements**

---

| | |
|:---|:---|
| &nbsp;&nbsp;[Balance Sheets at June 30, 2022 and 2021](#bs2) | &nbsp;&nbsp;F-1 |
| &nbsp;&nbsp;[Statements of Operations for the six months ended June 30, 2022 and 2021](#sop2) | &nbsp;&nbsp;F-2 |
| &nbsp;&nbsp;[Statements of Stockholders' Equity for the six months ended June 30, 2022 and 2021](#sse2) | &nbsp;&nbsp;F-3 |
| &nbsp;&nbsp;[Statements of Cash Flows for the six months ended June 30, 2022 and 2021](#cfs2) | &nbsp;&nbsp;F-4 |
| &nbsp;&nbsp;[Notes to Financial Statements, June 30, 2022 and 2021](#notes2) | &nbsp;&nbsp;F-5 |
| &nbsp;&nbsp;[Report of Independent Registered Public Accounting Firm](#report) | &nbsp;&nbsp;F-13 |
| &nbsp;&nbsp;[Balance Sheets at December 31, 2021, September 30, 2021 and 2020](#bs) | &nbsp;&nbsp;F-14 |
| &nbsp;&nbsp;[Statements of Operations for the three months ended December 31, 2021 and years ended September 30, 2021 and 2020](#sop) | &nbsp;&nbsp;F-15 |
| &nbsp;&nbsp;[Statements of Stockholders' Equity for the three months ended December 31, 2021 and years ended September 30, 2021 and 2020](#sse) | &nbsp;&nbsp;F-16 |
| &nbsp;&nbsp;[Statements of Cash Flows for the three months ended December 31, 2021 and years ended September 30, 2021 and 2020](#cfs) | &nbsp;&nbsp;F-17 |
| &nbsp;&nbsp;[Notes to Financial Statements](#notes) | &nbsp;&nbsp;F-18 |

---

------

**LEE PHARMACEUTICALS, INC.**

**CONDENSED CONSOLIDATED UNAUDITED FINANCIAL STATEMENTS**

**BALANCE SHEETS**

---

| | | | |
|:---|:---|:---|:---|
|  |  | **June 30,** | **December 31,** |
|  | **Notes** | **2022** | **2021** |
| **ASSETS** |  |  |  |
| Current assets |  |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | 2 | $13168 | $- |
| &nbsp;&nbsp;&nbsp;Deposits & prepayments | 5 | - | 13171 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets |  | 13168 | 13171 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets |  | $13168 | $13171 |
| **LIABILITIES AND STOCKHOLDERS' DEFICIT** |  |  |  |
| Current liabilities: |  |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable, trade |  | $- | $- |
| &nbsp;&nbsp;&nbsp;Accrued expenses |  | - | - |
| &nbsp;&nbsp;&nbsp;Loans & notes payable, s/t or current, net of<br> &nbsp;&nbsp;&nbsp;&nbsp;unamortized debt discount of $171,311 | 6 | 130634 | - |
| &nbsp;&nbsp;&nbsp;Related party loans & notes payable, short-term<br> &nbsp;&nbsp;&nbsp;&nbsp;or current | 10 | 25 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities |  | 555295 | - |
| **Total liabilities** |  | 555295 | - |
| **Stockholders' equity (deficit)** |  |  |  |
| &nbsp;&nbsp;&nbsp;Preferred stock Series A: par value $0.001,<br> &nbsp;&nbsp;&nbsp;&nbsp;10 authorized and 10 issued and outstanding<br> &nbsp;&nbsp;&nbsp;&nbsp;at June 30, 2022 and December 31, 2021 |  | - | - |
| &nbsp;&nbsp;&nbsp;Common stock: par value $0.001,<br> &nbsp;&nbsp;&nbsp;&nbsp;7,500,000 authorized and 5,162,350 issued<br> &nbsp;&nbsp;&nbsp;&nbsp;and outstanding at June 30, 2022 and<br> &nbsp;&nbsp;&nbsp;&nbsp;December 31, 2021 |  | 5162 |  |
| &nbsp;&nbsp;&nbsp;Additional paid in capital |  | 4769806 | 5162 |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive income (loss) |  | - | 4769806 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit |  | (5317095) | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity (deficit) |  | (542127) | (4761797) |
| Total liabilities and stockholders' equity (deficit) |  | $13168 | $13171 |

---

The accompanying notes are an integral part of these financial statements

------

**LEE PHARMACEUTICALS, INC.**

**STATEMENTS OF OPERATIONS**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended**<br> **June 30,** | **Three Months Ended**<br> **June 30,** | **Six Months Ended**<br> **June 30,** | **Six Months Ended**<br> **June 30,** |
|  | **2022** | **2021** | **2022** | **2021** |
| Revenues | $- | $- | $- | $- |
| Cost of goods sold | - | - | - | - |
| Gross profit | - | - | - | - |
| **Operating expenses:** |  |  |  |  |
| Selling, general and administrative expenses | 192342 | - | 205513 | - |
| **Total operating expenses** | 192342 | - | 205513 | - |
| Net operating income (loss) | (192342) | - | (205513) | - |
| Net income (loss) before income taxes | (542127) | - | (555298) | - |
| Provision for corporation taxes | - | - | - | - |
| Net income (loss) | $(542127) | $- | $(555298) | $- |
| **Net income (loss) per share** | $(0.11) | $(0.00) | $(0.11) | $(0.00) |
| **Weighted average shares outstanding** | 5162350 | 5162350 | 5162350 | 5162350 |

---

The accompanying notes are an integral part of these financial statements

------

**LEE PHARMACEUTICALS, INC.**

**CONDENSED CONSOLIDATED UNAUDITED FINANCIAL STATEMENTS**

**STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Preferred Stock** | **Preferred Stock** | **Common Stock** | **Common Stock** | **Additional**<br> **Paid-In** | **Accumulated** |  |
|  | **Shares** | **Value** | **Shares** | **Value** | **Capital** | **Surplus (Deficit)** | **Total** |
| **Balance, January 1, 2021** | - | $- | 5162350 | $5162 | $4733088 | $(4738250) | $- |
| Preferred stock issued<br> to repay debt | 10 | - | - | - | 36718 | - | 36718 |
| Net loss | - | - | - | - | - | (23547) | (23547) |
| **Balance, December 31, 2021** | 10 | - | 5162350 | 5162 | 4769806 | (4761797) | 13171 |
| **Balance, January 1, 2022** | 10 | - | 5162350 | 5162 | 4769806 | (4761797) | 13171 |
| Net loss | - | - | - | - | - | (555298) | (555298) |
| **Balance, June 30, 2022** | 10 | $- | 5162350 | $5162 | $4769806 | $(5317095) | $(542127) |

---

The accompanying notes are an integral part of these financial statements

------

**LEE PHARMACEUTICALS, INC.**

**STATEMENTS OF CASH FLOWS**

---

| | | |
|:---|:---|:---|
|  | **Six Months Ended**<br> **June 30,** | **Six Months Ended**<br> **June 30,** |
|  | **2022** | **2021** |
| **CASH FLOWS FROM OPERATING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;Net income (loss) | $(555298) | $- |
| Adjustments to reconcile net income (loss) to net cash provided<br> by (used in) operating activities: |  |  |
| &nbsp;&nbsp;Amortization of debt discount | 91347 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;(Gain) loss on revaluation of derivative liability | (29576) | - |
| &nbsp;&nbsp;Financing costs | 288014 | - |
| Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;Accounts receivable | - | - |
| &nbsp;&nbsp;Other current assets | 13171 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities | (192342) | - |
| **CASH FLOWS FROM INVESTING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;Sale (purchase) of tangible assets | - | - |
| &nbsp;&nbsp;Sale (purchase) of intangible assets | - | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by investing activities | - | - |
| **CASH FLOWS FROM FINANCING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;Proceeds from (repayment of) debt instruments | 493499 | - |
| &nbsp;&nbsp;Related party loans | 25 | - |
| &nbsp;&nbsp;Financing costs | (288014) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities | 205510 | - |
| **NET INCREASE IN CASH** | 13168 | - |
| **CASH, BEGINNING OF PERIOD** | - | - |
| **CASH, END OF PERIOD** | $13168 | $- |

---

The accompanying notes are an integral part of these financial statements

------

**LEE PHARMACEUTICALS, INC.**

**CONDENSED CONSOLIDATED UNAUDITED FINANCIAL STATEMENTS**

**NOTES FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022**

**NOTE 1. NATURE AND BACKGROUND OF BUSINESS**

The accompanying consolidated financial statements include Lee Pharmaceuticals, Inc. (the 'Company', 'we' or 'us'), a Colorado corporation, its wholly-owned subsidiaries and any majority controlled interests.

The Company was formed in April 1971, and, until recently, specialized in personal care products such as cough and cold remedies, lip balms, nasal sprays, depilatories, laxatives, oral care, creams, and ointments. The Company is now evaluating business direction and potential acquisitions with decisions and strategy being announced in 2022.

On January 10, 2022, the Company's then CEO, Benjamin Berry, sold his ten (10) shares of Series A Preferred Stock to Accelerate Global Market Solutions Corp. for $150,000 in cash, effecting a change of control. As part of this transaction, John Morgan was appointed the Company's new CEO.

On April 7, 2022, the Company acquired Accelerate Global Market Solutions Corp and its assets and liabilities.

**NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Basis of Presentation**

The accompanying financial statements have been prepared for Lee Pharmaceuticals, Inc. in accordance with accounting principles generally accepted in the United States of America (US GAAP), with all numbers shown in US Dollars.

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation of the financial statements have been included. The financial statements include acquired subsidiaries, as discussed below, and include all consolidation entries required to include those subsidiaries.

**Use of Estimates**

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

**Revenue Recognition**

The Company recognizes revenue in accordance with Accounting Standards Update ("ASU") 2014-09, "Revenue from contracts with customers," (Topic 606). Revenue is recognized when a customer obtains control of promised goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company expects to recognize revenues as the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied.

------

**Cash and Cash Equivalents**

For the Balance Sheet and Statement of Cash Flows, all highly liquid investments with maturity of three months or less are considered to be cash equivalents. The Company had no cash equivalents as at June 30, 2022 or December 31, 2021.

**Income Taxes**

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss, capital loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits as a component of general and administrative expenses. Our federal tax return and any state tax returns are not currently under examination.

Income taxes are provided in accordance with the FASB Accounting Standards (ASC 740), Accounting for Income Tax. A deferred tax asset or liability is recorded for all temporary differences between financial and tax reporting and net operating loss carry forwards. Any deferred tax expense (benefit) resulting from the net change during the year is shown as deferred tax assets and liabilities. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it was more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

**Basic and Diluted Net Income (Loss) Per Share**

Net income (loss) per unit is calculated in accordance with Codification topic 260, "Earnings per Share" for the periods presented. Basic net loss per share is computed using the weighted average number of common shares outstanding. Diluted loss per share has not been presented because the shares of common stock equivalents have not been included in the per share calculations as such inclusion would be anti-dilutive. Diluted earnings per share is based on the assumption that all dilutive stock options, warrants and convertible debt are converted or exercised applying the treasury stock method. Under this method, options, warrants and convertible debt are assumed exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase shares of common stock at the average market price during the period. Options, warrants and/or convertible debt will have a dilutive effect during periods of net profit only when the average market price of the units during the period exceeds the exercise or conversion price of the items.

**Stock Based Compensation**

Codification topic 718 "Stock Compensation" requires that the cost resulting from all share-based transactions be recorded in the financial statements and establishes fair value as the measurement objective for share-based payment transactions with employees and acquired goods or services from non-employees. The codification also provides guidance on valuing and expensing these awards, as well as disclosure requirements of these equity arrangements. The Company adopted the codification upon creation of the Company and will expense share-based costs in the period incurred. The Company has not yet adopted a stock option plan and all share-based transactions and share based compensation has been expensed in accordance with the codification guidance.

**Convertible Instruments**

The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with professional standards for "Accounting for Derivative Instruments and Hedging Activities". Professional standards generally provide three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instruments are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re- measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur, and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is

------

deemed to be conventional as defined under professional standards as "The Meaning of Conventional Convertible Debt Instrument".<br>

The Company accounts for convertible instruments when it has determined that the embedded conversion options should not be bifurcated from their host instruments in accordance with professional standards when "Accounting for Convertible Securities with Beneficial Conversion Features," as those professional standards pertain to "Certain Convertible Instruments." Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying shares of common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares of common stock based upon the differences between the fair value of the underlying shares at the commitment date of the note transaction and the effective conversion price embedded in the note.

ASC 815-40 provides that, among other things, generally, if an event not within the entity's control could require net cash settlement, then the contract shall be classified as an asset or a liability.

**Fair Value of Financial Instruments**

We adopted the guidance of ASC-820 for fair value instruments, which clarifies the definition of fair value, prescribes methods for determining fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value, as follows:

Level 1Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.

Level 2Inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.

Level 3Inputs are unobservable inputs which reflect the reporting entity's own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.

The carrying amounts for cash, accounts receivable, accounts payable and accrued expenses, and loans payable approximate their fair value based on the short- term maturity of these instruments. We identified assets or liabilities that are required to be presented on the balance sheet at fair value in accordance with the accounting guidance as at June 30, 2022, as detailed in Note 11, Derivative Liabilities, and no such assets or liabilities as at December 31, 2021.

ASC 825-10 "Financial Instruments" allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. We elected to apply the fair value option to outstanding instruments.

**Derivative Liabilities**

Derivative financial instruments consist of convertible instruments and rights to shares of the Company's common stock. The Company assessed that it had derivative liabilities as at June 30, 2022, as detailed in Note 11, Derivative Liabilities, and no derivative liabilities as at December 31, 2021.

ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirement of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional, as described.

------

**Impact of New Accounting Standards**

The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company's results of operations, financial position, or cash flow.

**NOTE 3. GOING CONCERN**

The Company's financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern. This contemplates the realization of assets and the liquidation of liabilities in the normal course of business. Realization values may be substantially different from carrying values as shown and these financial statements do not give effect to adjustments that would be necessary to the carrying values and classification of assets and liabilities should the Company be unable to continue as a going concern. Currently, the Company does not have significant cash or other material assets, nor does it have operations or a source of revenue sufficient to cover its operation costs and allow it to continue as a going concern.

The Company has a limited operating history and had a cumulative net loss from inception to June 30, 2022 of $5,317,095. The Company has a working capital deficit of $542,127 as at June 30, 2022.

These financial statements for the six months ended June 30, 2022 have been prepared assuming the Company will continue as a going concern, which is dependent upon the Company's ability to generate future profits and/or obtain necessary financing to meet its obligations as they come due.

The management has committed to an aggressive growth plan for the Company. The Company's future operations are dependent upon external funding and its ability to execute its business plan, realize sales and control expenses. Management believes that sufficient funding will be available from additional borrowings and private placements to meet its business objectives including anticipated cash needs for working capital, for a reasonable period of time. However, there can be no assurance that the Company will be able to obtain sufficient funds to continue the development of its business operation, or if obtained, upon terms favorable to the Company.

**NOTE 4. ACQUISITIONS AND DISPOSALS**

The Company acquired Accelerate Global Market Solutions Corp ('Accelerate') on April 7, 2022, and its assets of the control block of preferred stock recently acquired and the liability of the loan note due to World Market Ventures LLC. The preferred stock was issued to the CEO, John Morgan, and the loan note was retained by the Company. The acquisition was effected by the owner, John Morgan, contributing Accelerate to the Company.

**NOTE 5. OTHER CURRENT ASSETS**

The Company had the following current assets as at June 30, 2022 and December 31, 2021.

---

| | | |
|:---|:---|:---|
|  | &nbsp;&nbsp;**June 30, 2022** | &nbsp;&nbsp;**December 31, 2021** |
| &nbsp;&nbsp;Prepayments of business expenses, paid by then CEO | $&nbsp;&nbsp;- | $&nbsp;&nbsp;13171 |
| &nbsp;&nbsp;Other debtors | &nbsp;&nbsp;- | &nbsp;&nbsp;- |
| &nbsp;&nbsp;Totals | $&nbsp;&nbsp;**-** | $&nbsp;&nbsp;**13171** |

---

------

**NOTE 6. LOANS AND NOTES PAYABLE**

The Company had loans and notes payable as at June 30, 2022 and December 31, 2021 totaling $214,787 and nil respectively, as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**Description** | &nbsp;&nbsp;**Principal**<br> **Amount** | &nbsp;&nbsp;**Date of Loan**<br> **Note** | &nbsp;&nbsp;**Maturity**<br> **Date** | &nbsp;&nbsp;**June 30,**<br> **2022** | &nbsp;&nbsp;**December 31,**<br> **2021** |
| &nbsp;&nbsp;Convertible loan from World Market Ventures, 6 months, 9% interest, convertible at 50% of lowest price during term | &nbsp;&nbsp;$170500 | &nbsp;&nbsp;4/7/2022 | &nbsp;&nbsp;10/7/2022 | &nbsp;&nbsp;$174031 | &nbsp;&nbsp;$- |
| &nbsp;&nbsp;Promissory note from JP Carey Limited Partners LP, 12 months, 10% interest, non-convertible | &nbsp;&nbsp;40000 | &nbsp;&nbsp;4/22/2022 | &nbsp;&nbsp;4/22/2023 | &nbsp;&nbsp;40756 | &nbsp;&nbsp;- |
| &nbsp;&nbsp;Total |  |  |  | &nbsp;&nbsp;$214787 | &nbsp;&nbsp;$- |
| &nbsp;&nbsp;Long-term total |  |  |  | &nbsp;&nbsp;- | &nbsp;&nbsp;- |
| &nbsp;&nbsp;Short-term total |  |  |  | &nbsp;&nbsp;$214787 | &nbsp;&nbsp;$- |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Loans and Notes Amortization** | &nbsp;&nbsp;**Amount Due** |
| &nbsp;&nbsp;Due within 12 months | $&nbsp;&nbsp;214787 |
| &nbsp;&nbsp;Due within 24 months | &nbsp;&nbsp;- |
| &nbsp;&nbsp;Due within 36 months | &nbsp;&nbsp;- |
| &nbsp;&nbsp;Due within 48 months | &nbsp;&nbsp;- |
| &nbsp;&nbsp;Due after 48 months | &nbsp;&nbsp;- |
| &nbsp;&nbsp;Total | $&nbsp;&nbsp;214787 |

---

**NOTE 7. CAPITAL STOCK**

As at June 30, 2022 and December 31, 2021, the Company was authorized to issue Preferred Stock and Common Stock as detailed below.

**Preferred Stock**

At June 30, 2022 the Company had authorized Preferred Stock in one designation totaling 10 shares:

Preferred Stock Series AThe Company is authorized to issue 10 shares of Series A, with a par value of $0.001 per share. Each shares of preferred stock converts into 10,000,000 shares of common stock, and the holder of the preferred stock are entitled to a vote representing 60% of all votes cast. The shares do not pay a dividend. As at January 1, 2020, the Company had no shares of Series A preferred stock issued and outstanding.

On September 30, 2021 the Company issued 10 shares of Preferred Stock Series A to a debt holder for debt conversion of $36,718, or $3671.8 per share.

At June 30, 2022 the Company had 10 shares of Preferred Stock Series A issued and outstanding.

As at June 30, 2022, the Company had a total of 10 shares of Preferred Stock issued and outstanding.

------

**Common Stock**

As at June 30, 2022, the Company was authorized to issue up to 7,500,000 shares of Common Stock with par value of $0.001 per share. On August 1, 2022, the Company increased its authorized share capital to 500,000,000 shares.

As at January 1, 2021, the Company had 5,162,350 shares of Common Stock issued and outstanding. As at June 30, 2022, there were 5,162,350 shares of Common Stock issued and outstanding.

**NOTE 8. DERIVATIVE LIABILITIES**

The Company applies the provisions of ASC Topic 815-40, Contracts in Entity's Own Equity ("ASC Topic 815-40"), under which convertible instruments, which contain terms that protect holders from declines in the stock price (reset provisions), may not be exempt from derivative accounting treatment. As a result, embedded conversion options in convertible debt are recorded as a liability and are revalued at fair value at each reporting date. If the fair value of the note exceeds the face value of the related debt, the excess is recorded as change in fair value in operations on the issuance date.

The Company identified embedded derivatives related to the Convertible Loan Note issued on April 7, 2022 totaling $170,500, including original issuer discount of $15,500. These embedded derivatives included certain conversion features. The accounting treatment of derivative financial instruments requires that the Company record the fair value of the derivatives as of the inception date of the Convertible Promissory Note and to adjust the fair value as of each subsequent balance sheet date. At the inception of the Convertible Promissory Note, the Company determined a fair value for the embedded derivative using the Black Scholes Model based on the following assumptions:

---

| | |
|:---|:---|
| Dividend yield | 0.00% |
| Volatility | 516.61% |
| Risk-free rate | 2.70% |

---

The initial fair value of the embedded debt derivative was $454,212. The proceeds of the note of $170,500 was allocated as a debt discount. The amount in excess of the proceeds of the loan note of $283,712 was charged as interest to the Statement of Operations for the period.

The fair value of the embedded debt derivative was reviewed at June 30, 2022, using the following inputs:

---

| | |
|:---|:---|
| Dividend yield | 0.00% |
| Volatility | 509.99% |
| Risk-free rate | 3.15% |

---

The fair value of the embedded debt derivative at June 30, 2022 was $424,636, a decrease in the valuation of the embedded debt derivative of $29,576 for the period.

The following table provides a summary of changes in fair value of the Company's Level 3 derivative liabilities as at June 30, 2022:

---

| | | |
|:---|:---|:---|
|  | &nbsp;&nbsp;**June 30, 2022** | &nbsp;&nbsp;**December 31, 2021** |
| &nbsp;&nbsp;Balance, beginning of period | $&nbsp;&nbsp;- | $&nbsp;&nbsp;- |
| &nbsp;&nbsp;Additions | &nbsp;&nbsp;454212 | &nbsp;&nbsp;- |
| &nbsp;&nbsp;Mark-to-market at modification date | &nbsp;&nbsp;(29576) | &nbsp;&nbsp;- |
| &nbsp;&nbsp;Reclassified to additional paid-in capital upon modification of term | &nbsp;&nbsp;- | &nbsp;&nbsp;- |
| &nbsp;&nbsp;Balance, June 30, 2022 | &nbsp;&nbsp;424636 | &nbsp;&nbsp;- |
| &nbsp;&nbsp;Net gain due to change in fair value for the period included in statement of operations | $&nbsp;&nbsp;29576 | $&nbsp;&nbsp;- |

---

This mark-to-market decrease of $29,576 for the period ended June 30, 2022 was charged to the statement of operations as a gain on change in value of derivative liabilities.

------

**NOTE 9. INCOME TAXES**

The Company uses the assets and liability method of accounting for income taxes pursuant to SFAS No. 109 "Accounting for Income Taxes". Under the assets and liability method of SFAS No. 109, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

In June 2006, the FASB issued FASB Interpretation No. 48, "Accounting for Uncertainty in Income Taxes." Specifically, the pronouncement prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken from year ended December 31, 2015 tax return onwards. The interpretation also provides guidance on the related derecognition, classification, interest and penalties, accounting for interim periods, disclosure and transition of uncertain tax positions. The Company adopted this interpretation effective on inception.

For the year ended December 31, 2021, the Company had available for US federal income tax purposes net operating loss carryovers of $4,761,797, all of which will expire by 2041.

The Company has provided a full valuation allowance against the full amount of the net operating loss benefit, since, in the opinion of management, based upon the earnings history of the Company, it is more likely than not that the benefits will not be realized.

---

| | | |
|:---|:---|:---|
|  | &nbsp;&nbsp;**June 30, 2022** | &nbsp;&nbsp;**December 31, 2021** |
| &nbsp;&nbsp;Statutory federal income tax rate | &nbsp;&nbsp;21.00% | &nbsp;&nbsp;21.00% |
| &nbsp;&nbsp;Statutory state income tax rate | &nbsp;&nbsp;0.00% | &nbsp;&nbsp;0.00% |
| &nbsp;&nbsp;Valuation allowance | &nbsp;&nbsp;(21.00%) | &nbsp;&nbsp;(21.00%) |
| &nbsp;&nbsp;Effective tax rate | &nbsp;&nbsp;0.00% | &nbsp;&nbsp;0.00% |

---

Deferred income taxes result from temporary differences in the recognition of income and expenses for financial reporting purposes and for tax purposes. The tax effect of these temporary differences representing deferred tax assets result principally from the following:

---

| | | |
|:---|:---|:---|
|  | &nbsp;&nbsp;**June 30, 2022** | &nbsp;&nbsp;**December 31, 2021** |
| &nbsp;&nbsp;**Deferred Tax Assets (Gross Values)** |  |  |
| &nbsp;&nbsp;Net operating loss carry forward | $&nbsp;&nbsp;(4892459) | $&nbsp;&nbsp;(4761797) |
| &nbsp;&nbsp;Less valuation allowance | &nbsp;&nbsp;4892459 | &nbsp;&nbsp;4761797 |
| &nbsp;&nbsp;Net deferred tax asset | $&nbsp;&nbsp;- | $&nbsp;&nbsp;- |

---

**NOTE 10. RELATED PARTY TRANSACTIONS**

The Company had the following related party transactions during the six months ended June 30, 2022 or year ending December 31, 2021.

During the period ended September 30, 2021, Synergy Management Group, a Company owned by the CEO, paid $3,930 in expenses on behalf of the Company. Additionally, the related party estimated an additional $32,788 that it would pay in expenses on behalf of the Company. The Company issued 10 Series A Convertible Preferred Shares in lieu of these payments.

During the three months ended December 31, 2021, an additional $19,617 in expenses were paid and $13,171 remained as prepaid expenses on the balance sheet. During the three months ended March 31, 2022, the remaining $13,171 prepaid expenses were expensed and are shown in the operating statement.

------

**NOTE 11. SUBSEQUENT EVENTS**

Subsequent to June 30, 2022, the Company reported the following events:

On August 1, 2022, the Company increased the authorized capital for its shares of common stock from 7,500,000 to 500,000,000, still at par value $0.001 per share.

------

![img.png](lphm253g1_1.jpg)

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

To the Board of Directors and Stockholders of Lee Pharmaceuticals, Inc.

**Opinion on the Financial Statements**

We have audited the accompanying balance sheets of Lee Pharmaceuticals, Inc. (the Company) as of December 31, 2021, September 30, 2021 and 2020, and the related statements of operations, stockholders' equity, and cash flows for the three month period ended December 31, 2021 and the each of the years in the two-year period ended September 30, 2021, and the related notes and schedules (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021, September 30, 2021 and 2020, and the results of its operations and its cash flows for the three month period ended December 31, 2021 and each of the years in the two-year period ended September 30, 2021, in conformity with accounting principles generally accepted in the United States of America.

**Basis for Opinion**

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

**Critical Audit Matters**

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there were no critical audit matters.

**Substantial Doubt about the Company's Ability to Continue as a Going Concern**

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has suffered recurring losses from operations and negative operating cash flows since inception. These conditions raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

We have served as the Company's auditor since 2021.

Tampa, Florida March 15, 2022

*/s/ Accell Audit & Compliance, PA*

3001 N. Rocky Point Dr. East, Suite 200 \* Tampa, Florida 33607 \* 813.367.3527

------

**LEE PHARMACEUTICALS, INC.**

**BALANCE SHEETS**

---

| | | | |
|:---|:---|:---|:---|
|  | **December 31,** | **September 30,** | **September 30,** |
|  | **2021** | **2021** | **2020** |
| **ASSETS** |  |  |  |
| Current assets |  |  |  |
| &nbsp;&nbsp;&nbsp;Cash | $- | $- | $- |
| &nbsp;&nbsp;&nbsp;Prepaid expenses | 13171 | 32788 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 13171 | 32788 | - |
| Property and equipment, net | - | - | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $13171 | $32788 | $- |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |  |
| Current liabilities: |  |  |  |
| Accounts payable | $- | $- | $- |
| Other current liabilities | - | - | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | - | - | - |
| Notes payable | - | - | - |
| Other miscellaneous liabilities | - | - | - |
| **Total liabilities** | - | - | - |
| Commitments and contingencies (Note 4) |  |  |  |
| **Stockholders' equity** |  |  |  |
| &nbsp;&nbsp;&nbsp;Preferred stock, $0.001 par value,<br> &nbsp;&nbsp;&nbsp;&nbsp;10 shares authorized; |  |  |  |
| &nbsp;&nbsp;&nbsp;Series A preferred stock: 10 shares authorized;<br> &nbsp;&nbsp;&nbsp;&nbsp;10, 10 and 0 shares issued and outstanding at<br> &nbsp;&nbsp;&nbsp;&nbsp;December 31, 2021, September 30, 2021 and 2020 | - | - | - |
| &nbsp;&nbsp;&nbsp;Common stock, $0.001 par value; 7,500,000 shares<br> &nbsp;&nbsp;&nbsp;&nbsp;authorized 5,162,500 issued and outstanding | 5162 | 5162 | 5162 |
| &nbsp;&nbsp;&nbsp;Additional paid in capital | 4769806 | 4769806 | 4733088 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (4761797) | (4742180) | (4738250) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 13171 | 32788 | - |
| Total liabilities and stockholders' equity | $13171 | $32788 | $- |

---

The accompanying notes are an integral part of these financial statements

------

**LEE PHARMACEUTICALS, INC.**

**STATEMENTS OF OPERATIONS**

---

| | | | |
|:---|:---|:---|:---|
|  | **For the three**<br> **months ended**<br> **December 31,** | **For the twelve**<br> **months ended**<br> **September 30,** | **For the twelve**<br> **months ended**<br> **September 30,** |
|  | **2021** | **2021** | **2020** |
| Revenues | $- | $- | $- |
| Cost of goods sold | - | - | - |
| Gross profit | - | - | - |
| **Operating expenses:** |  |  |  |
| Professional fees | 5022 | 1000 | - |
| Management fees, related party | 13316 | - | - |
| General and administrative expenses | 1279 | 2930 | - |
| **Total operating expenses** | 19617 | 3930 | - |
| Income tax benefit (expense) | - | - | - |
| Net income (loss) | $(19617) | $(3930) | $- |
| **Basic and diluted loss per share** | $(0.00) | $(0.00) | $(0.00) |
| **Weighted average number of shares outstanding, basic and diluted** | 5162500 | 5162500 | 5162500 |

---

The accompanying notes are an integral part of these financial statements

------

**LEE PHARMACEUTICALS, INC.**

**STATEMENTS OF STOCKHOLDERS' EQUITY**

**FOR THE THREE MONTH PERIOD ENDED DECEMBER 31, 2021 AND**

**THE YEARS ENDED SEPTEMBER 30, 2021 AND 2020**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Preferred Stock**<br> **Series A** | **Preferred Stock**<br> **Series A** | **Common Stock** | **Common Stock** | **Additional**<br> **Paid-In** | **Accumulated** |  |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Capital** | **Deficit** | **Total** |
| **Balance, September 30, 2018** | - | $- | 5162500 | $5162 | $4733088 | $(4738250) | $- |
| Net loss | - | - | - | - | - | - | - |
| **Balance, September 30, 2019** | - | - | 5162500 | 5162 | 4733088 | (4738250) | - |
| Net income (loss) | - | - | - | - | - | - | - |
| **Balance, September 30, 2020** | - | - | 5162500 | 5162 | 4733088 | (4738250) | - |
| Series A Preferred Stock issued<br> for prepaid expenses | 10 | - | - | - | 36718 | - | 36718 |
| Net income (loss) | - | - | - | - | - | (3930) | (3930) |
| **Balance, September 30, 2021** | 10 | - | 5162500 | 5162 | 4769806 | (4742180) | 32788 |
| Net income (loss) | - | - | - | - | - | (19617) | (19617) |
| **Balance, December 31, 2021** | 10 | $- | 5162500 | $5162 | $4769806 | $(4761797) | $13171 |

---

The accompanying notes are an integral part of these financial statements

------

**LEE PHARMACEUTICALS, INC.**

**STATEMENTS OF CASH FLOWS**

---

| | | | |
|:---|:---|:---|:---|
|  | **For the three**<br> **months ended**<br> **December 31,** | **For the twelve**<br> **months ended**<br> **September 30,** | **For the twelve**<br> **months ended**<br> **September 30,** |
|  | **2021** | **2021** | **2020** |
| **CASH FLOWS FROM OPERATING ACTIVITIES:** |  |  |  |
| Net income (loss) | $(19617) | $(3930) | $- |
| Changes in working capital requirements: |  |  |  |
| &nbsp;&nbsp;Prepaid expenses | 19617 | 3930 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities | - | - | - |
| **CASH FLOWS FROM INVESTING ACTIVITIES:** |  |  |  |
| &nbsp;&nbsp;Investments | - | - | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash (used in) provided by investing activities | - | - | - |
| **CASH FLOWS FROM FINANCING ACTIVITIES:** |  |  |  |
| &nbsp;&nbsp;Proceeds from / payments on notes payable | - | - | - |
| &nbsp;&nbsp;Proceeds from common stock | - | - | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities | - | - | - |
| **NET INCREASE IN CASH** | - | - | - |
| **CASH, BEGINNING OF PERIOD** | - | - | - |
| **CASH, END OF PERIOD** | $- | $- | $- |
| Supplemental disclosure of cash flow information |  |  |  |
| &nbsp;&nbsp;Cash paid for interest expense | $- | $- | $- |
| &nbsp;&nbsp;Cash paid for income taxes | $- | $- | $- |

---

The accompanying notes are an integral part of these financial statements

------

**LEE PHARMACEUTICALS, INC.**

**NOTES TO FINANCIAL STATEMENTS**

**FOR THE THREE MONTH PERIOD ENDED DECEMBER 31, 2021 AND**

**YEARS ENDED SEPTEMBER 30, 2021 AND 2020**

**1.** **Nature of operations**

Lee Pharmaceuticals, Inc. (the "Company") was formed in April of 1971. Lee Pharmaceuticals, Inc. previously specialized in personal care products such as cough and cold, lip balms, nasal sprays, depilatories, laxatives, oral care, creams and ointments. The Company is now evaluating business direction and potential acquisitions with decisions and strategy being announced in 2022. On September 20, 2021, the Company changed their year end from September 30th to December 31<sup>st</sup>.

**2.** **Summary of significant accounting policies**

Basis of Presentation

The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP").

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of equity issued for services. Actual results could differ from these estimates.

Revenue Recognition

The Company recognizes revenue in accordance with Accounting Standards Update ("ASU") 2014-09, "Revenue from contracts with customers," (Topic 606). Revenue is recognized when a customer obtains control of promised goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company expects to recognize revenues as the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied.

------

Fair Value Measurements and Fair Value of Financial Instruments

The Company adopted ASC Topic 820, Fair Value Measurements. ASC Topic 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:

Level 1:Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.

Level 2:Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.

Level 3:Inputs are unobservable inputs which reflect the reporting entity's own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.

The estimated fair value of certain financial instruments, including all current liabilities are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

Fair Value of Financial Instruments

ASC subtopic 825-10, Financial Instruments ("ASC 825-10") requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities when reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows ASC subtopic 820-10, Fair Value Measurements and Disclosures ("ASC 820-10") and ASC 825-10, which permits entities to choose to measure many financial instruments and certain other items at fair value.

Cash and Cash Equivalents

For purposes of the Statements of Cash Flows, the Company considers highly liquid investments with an original maturity of three months or less to be cash equivalents.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss, capital loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits as a component of general and administrative expenses. Our federal tax return and any state tax returns are not currently under examination.

------

The Company has adopted FASB ASC 740-10, Accounting for Income Taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually from differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

Net Income (Loss) Per Common Share

The Company computes loss per common share, in accordance with FASB ASC Topic 260, Earnings Per Share, which requires dual presentation of basic and diluted earnings per share. Basic income or loss per common share is computed by dividing net income or loss by the weighted average number of common shares outstanding during the period. Diluted income or loss per common share is computed by dividing net income or loss by the weighted average number of common shares outstanding, plus the issuance of common shares, if dilutive, that could result from the exercise of outstanding stock options and warrants.

Recent Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

**3.** **Going concern**

The accompanying financial statements have been prepared on a going concern basis. For the three month period ended December 31, 2021, the Company had a net loss of $19,617, had $13,171 in working capital, accumulated deficit of $4,761,797 and stockholders' equity of $13,171. These matters raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from the date of this filing. The Company's ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due, to fund possible future acquisitions, and to generate profitable operations in the future. Management plans to provide for the Company's capital requirements by continuing to issue additional equity and debt securities. The outcome of these matters cannot be predicted at this time and there are no assurances that, if achieved, the Company will have sufficient funds to execute its business plan or generate positive operating results. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

**4.** **Commitments and contingencies**

During the normal course of business, the Company may be exposed to litigation. When the Company becomes aware of potential litigation, it evaluates the merits of the case in accordance with FASB ASC 450-20-50, Contingencies. The Company evaluates its exposure to the matter, possible legal or settlement strategies and the likelihood of an unfavorable outcome. If the Company determines that an unfavorable outcome is probable and can be reasonably estimated, it establishes the necessary accruals. As of December 31, 2021, September 30, 2021 and 2020, the Company is not aware of any contingent liabilities that should be reflected in the financial statements.

**5.** **Related party transactions**

During the year ended September 30, 2021, Synergy Management Group, a Company owned by the CEO, paid $3,930 in expenses on behalf of the Company. Additionally, the related party estimated an additional $32,788 that it would pay in expenses on behalf of the Company. The Company issued 10 Series A Convertible Preferred Shares in lieu of these payments.

During the three months ended December 31, 2021, an additional $19,617 in expenses were paid and $13,171 remain as prepaid expenses on the balance sheets.

------

**6.** **Equity**

*Preferred Stock*

The Company has 10 Shares of Preferred Stock authorized, issued and outstanding with a par value of $0.001.

Series A - The Series A Preferred has the following designations:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Each share of preferred stock is convertible into 10,000,000 shares of common stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·The holders are not entitled to receive dividends

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Voting: The holder of this Series of Preferred shall be entitled to vote representing 60% of the votes eligible to be cast in the matter.

**7.** **Income taxes**

The Company adopted the provisions of uncertain tax positions as addressed in ASC 740-10-65-1. As a result of the implementation of ASC 740-10-65-1, the Company recognized no increase in the liability for unrecognized tax benefits. As of December 31, 2021 the Company had net operating loss carry forwards of $4,761,797 that may be available to reduce future years' taxable income in varying amounts through 2030. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards.

The valuation allowance at December 31, 2021 was approximately $999,977. The net change in valuation allowance during the three month period ended December 31, 2021 was $(4,119). In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized.

The components of the net deferred tax asset (liability) at December 31, 2021, September 30, 2021 and, 2020 and the statutory tax rate, the effective tax rate and the elected amount of the valuation allowance are indicated below:

---

| | | | |
|:---|:---|:---|:---|
|  | **December 31,**<br>**2021** | **September 30,**<br>**2021** | **September 30,**<br>**2020** |
| Net operating loss carry-forward | $999977 | $995858 | $995033 |
| Valuation Allowance | (999977) | (995858) | (995033) |
| Net Deferred Tax Asset (Liability) | $- | $- | $- |

---

Income tax benefit resulting from applying statutory rates in jurisdictions in which we are taxed (Federal and State of Florida) differs from the income tax provision (benefit) in our financial statements. The following table reflects the reconciliation for the three month period ended December 31, 2021 and years ended September 30, 2021 and 2020:

---

| | | | |
|:---|:---|:---|:---|
|  | | **Twelve Months Ended**<br> **September 30,** | **Twelve Months Ended**<br> **September 30,** |
|  | **Three Months Ended**<br> **December 31,**<br>**2021** | **2021** | **2020** |
| Benefit at federal and statutory rate | (21%) | (21%) | (21%) |
| Change in valuation allowance | 21% | 21% | 21% |
| Effective tax rate | 0% | 0% | 0% |

---

------

**8.** **Twelve Months Ended December 31, 2020 and Three Months Ending December 31, 2020 Comparative Data (Unaudited)**

The statement of income for the twelve months ended December 31, 2020 is as follows:

---

| | |
|:---|:---|
|  | **For the twelve months ended**<br> **December 31, 2020** |
|  | (Unaudited) |
| Revenues | $- |
| Cost of goods sold | - |
| Gross profit | - |
| **Operating expenses:** |  |
| Professional fees | - |
| Management fees, related party | - |
| General and administrative expenses | - |
| Total operating expenses | - |
| Income tax benefit (expense) | - |
| Net income (loss) | $- |
| **Basic and diluted loss per share** | $0.00 |
| **Weighted average number of shares outstanding, basic and diluted** | 5162500 |

---

The statement of income for the three months ended December 31, 2020 is as follows:

---

| | |
|:---|:---|
|  | **For the three months ended**<br> **December 31, 2020** |
|  | (Unaudited) |
| Revenues | $- |
| Cost of goods sold | - |
| Gross profit | - |
| **Operating expenses:** |  |
| Professional fees | - |
| Management fees, related party | - |
| General and administrative expenses | - |
| Total operating expenses | - |
| Income tax benefit (expense) | - |
| Net income (loss) | $- |
| **Basic and diluted loss per share** | $0.00 |
| **Weighted average number of shares outstanding, basic and diluted** | 5162500 |

---

------

**9.** **Subsequent Events**

On January 10, 2022, the Company's CEO sold his 10 shares of Series A Preferred Stock to Accelerate Global Market Solutions, Corp for $150,000 in cash. As part of the transaction, John Morgan was appointed as sole officer and Benjamin Berry resigned. Benjamin Berry agreed to stay on as a consultant until the company audit was completed.

------